var title_f37_16_38144="Mitomycin: Drug information";
var content_f37_16_38144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mitomycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F13906842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F13906843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/33/532?source=see_link\">",
"       Mitomycin (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/32/28166?source=see_link\">",
"       Mitomycin (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Mitomycin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $67.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $218.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $300.00",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9658 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38144=[""].join("\n");
var outline_f37_16_38144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/33/532?source=related_link\">",
"      Mitomycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/32/28166?source=related_link\">",
"      Mitomycin (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_16_38145="Dissection of the left mesocolon from Gerota fascia";
var content_f37_16_38145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Dissection of the left mesocolon from Gerota's fascia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 473px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The splenic flexure is mobilized by dissecting the left mesocolon from Gerota's fascia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38145=[""].join("\n");
var outline_f37_16_38145=null;
var title_f37_16_38146="Normal adult wrist AP xray";
var content_f37_16_38146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carpal bones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 612px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anterior posterior radiograph of the wrist shows the locations and names of the eight bones of the capus. The proximal row (from radial to ulnar) is composed of the scaphoid (also known as the navicular), lunate, triquetrum, and pisiform. In the distal row are the trapezium, trapezoid, capitate, and hamate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E. Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38146=[""].join("\n");
var outline_f37_16_38146=null;
var title_f37_16_38147="Sulfacetamide (topical): Pediatric drug information";
var content_f37_16_38147=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfacetamide (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?25/42/26276?source=see_link\">",
"    see \"Sulfacetamide (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/37/40531?source=see_link\">",
"    see \"Sulfacetamide (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9523091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Klaron&reg;;",
"     </li>",
"     <li>",
"      Ovace&reg;;",
"     </li>",
"     <li>",
"      Ovace&reg; Plus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9523092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sulfacet-R",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10527093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Sulfonamide Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10527103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/42/26276?source=see_link\">",
"      see \"Sulfacetamide (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Topical: Klaron&reg; Lotion: Apply thin film to affected area twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Seborrheic dermatitis, including seborrhea sicca:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ovace&reg; Plus Wash; Ovace&reg; Wash: Wash affected area twice daily; repeat application for 8-10 days. Dosing interval may be increased as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice daily regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ovace&reg; Plus Shampoo: Wash hair at least twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Secondary cutaneous bacterial infections:",
"     </b>",
"     Topical: Ovace&reg; Plus Wash; Ovace&reg; Wash: Wash affected area once daily for 8-10 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9523207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ovace&reg; Plus: 10% (57 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as sodium [emulsion-based/wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ovace&reg; Plus: 10% (355 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as sodium: 10% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klaron&reg;: 10% (118 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as sodium [wash]: 10% (177 mL, 354.8 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ovace&reg;: 10% (355 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad, topical, as sodium: 10% (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ovace&reg; Plus: 10% (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, topical, as sodium: 10% (118 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9523094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Lotion, pad, suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10527184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes and mucous membranes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Shake lotion well before using; apply a thin film to affected area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Shampoo: Apply to wet hair and massage vigorously into scalp; thoroughly rinse hair.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Wash: Apply to wet hair or skin and massage into a full lather; rinse thoroughly and pat dry; repeat after 10-20 seconds (for seborrheic dermatitis). If skin dryness occurs, rinse off early or use less frequently. Regular shampooing after use on hair is not necessary; however, hair should be shampooed at least once weekly.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13277357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Klaron&reg;: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ovace&reg; Plus Shampoo; Ovace&reg; Plus Wash; Ovace&reg; Wash: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from freezing or excessive heat.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical sulfacetamide preparations are incompatible with silver preparations.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10527094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of seborrheic dermatitis, seborrhea sicca, acne vulgaris, and secondary cutaneous bacterial infections due to organisms susceptible to sulfonamides (FDA approved in ages &ge;12 years and adults; refer to product specific information for FDA approved indications)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9523082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Klaron&reg; may be confused with Klor-Con&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9523139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning, edema (local), erythema, irritation, itching, stinging, Stevens-Johnson syndrome, systemic lupus erythematosus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10527095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfacetamide, any component, or sulfonamides; infants &lt;2 months of age",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10527098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes and mucous membranes. May cause reddening and/or scaling of the skin; use caution when applying to denuded or abraded skin. If irritation occurs, discontinue use. Use with caution in patients with G-6-PD deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10527097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities associated with sulfonamides, although rare, have occurred due to severe reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, systemic lupus erythematosus, hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias; discontinue use at first sign of rash or other adverse reaction. Hypersensitivity reactions may occur when a sulfonamide is readministered, irrespective of the route of administration. Antibacterial activity may be decreased in the presence of purulent exudates containing para-aminobenzoic acid (PABA); nonsusceptible organisms, such as fungi, may proliferate with prolonged or repeated use of sulfonamide preparations; hemolysis may occur in patients with G-6-PD deficiency. Some products contain sulfites which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9523141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9523101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9523102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. The amount of sulfacetamide available systemically following topical administration is unknown. Use of systemic sulfonamides during pregnancy may cause kernicterus in the newborn.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10527185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Response to therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10527100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10527101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Absorption: Poor through intact skin",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13277358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/37/40531?source=see_link\">",
"      see \"Sulfacetamide (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Do not cover with occlusive dressing; do not apply other lotions, creams, or medications to the area while using this medication. Report increased skin redness, irritation, joint pain, fever, or development of mouth sores; or if condition worsens or does not improve.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16048 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38147=[""].join("\n");
var outline_f37_16_38147=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523091\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523092\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527093\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527103\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523207\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523094\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527184\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277357\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527094\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523082\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523139\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527095\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527098\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527097\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300090\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523141\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523101\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523102\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527185\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527100\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527101\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277358\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16048\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16048|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/61/32723?source=related_link\">",
"      Sulfacetamide (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/55/18292?source=related_link\">",
"      Sulfacetamide (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/13/18643?source=related_link\">",
"      Sulfacetamide (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/42/26276?source=related_link\">",
"      Sulfacetamide (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/37/40531?source=related_link\">",
"      Sulfacetamide (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_16_38148="Diethylpropion: Patient drug information";
var content_f37_16_38148=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diethylpropion: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/23/8565?source=see_link\">",
"     see \"Diethylpropion: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tenuate&reg;;",
"     </li>",
"     <li>",
"      Tenuate&reg; Dospan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming; avoid long-term use. Use this drug as ordered by your doctor. Tell your doctor if you have a history of drug or alcohol abuse. Misuse of this drug may cause unsafe heart-related side effects. Tell your doctor if you have any heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat obesity.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701943",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diethylpropion or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703434",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Both attention deficit/hyperactivity problems and Tourette's syndrome or tics, high blood sugar (diabetes), drug abuse, glaucoma, heart disease, high blood pressure, nervous state, overactive thyroid disease, or structure problems of the heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often if you have heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698624",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11629 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-5480875BC6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38148=[""].join("\n");
var outline_f37_16_38148=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159808\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021560\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021562\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021561\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021566\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021567\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021569\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021564\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021565\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021570\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021571\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/23/8565?source=related_link\">",
"      Diethylpropion: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_16_38149="Haemophilus influenzae type b conjugate vaccine: Pediatric drug information";
var content_f37_16_38149=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Haemophilus influenzae type b conjugate vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?0/14/230?source=see_link\">",
"    see \"Haemophilus influenzae type b conjugate vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/32/14849?source=see_link\">",
"    see \"Haemophilus influenzae type b conjugate vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ActHIB&reg;;",
"     </li>",
"     <li>",
"      Hiberix&reg;;",
"     </li>",
"     <li>",
"      PedvaxHIB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ActHIB&reg;;",
"     </li>",
"     <li>",
"      PedvaxHIB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/14/230?source=see_link\">",
"      see \"Haemophilus influenzae type b conjugate vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants and Children 2 months to &lt;5 years (59 months): I.M.: 0.5 mL as a single dose; administer according to  \"brand-specific\" schedules (see table); preterm infants should be vaccinated based on chronological age (see table). ActHIB&reg; and PedvaxHIB&reg; are approved for a complete vaccine series; Hiberix&reg; is approved only as a booster dose (15-59 months) in children who have received primary immunization",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Vaccination Schedule for",
"      <b>",
"       <i>",
"        Haemophilus",
"       </i>",
"      </b>",
"      b Conjugate Vaccines",
"     </caption>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Age at 1st Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mo)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         ActHIB&reg;",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         PedvaxHIB&reg;",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary Series",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Booster",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary Series",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Booster",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Some combination vaccines containing Hib should not be used in infants &lt;6 months; consult product specific information prior to administration.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         At least 2 months after previous dose and &ge;12 months of age.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Hiberix&reg; may be used as a booster dose at 15-59 months (prior to 5 years of age)",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 doses,",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         2 months apart",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"         <sup>",
"          1,2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 doses,",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         2 months apart",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"         <sup>",
"          1,2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7-11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 doses,",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         2 months apart",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"         <sup>",
"          1,2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 doses,",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         2 months apart",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"         <sup>",
"          1,2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12-14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"         <sup>",
"          1,2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"         <sup>",
"          1,2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-71",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &mdash;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &mdash;",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:0em;\">",
"     Children &ge;5 years, Adolescents, and Adults who have not received the childhood Hib series",
"     <b>",
"      and",
"     </b>",
"     are at increased risk for invasive Hib disease due to certain chronic conditions [eg, sickle cell disease, leukemia, HIV infection, or splenectomy (ACIP recommendations)]: I.M.: One dose (0.5 mL); may use any of the Hib conjugate vaccines",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ActHIB&reg;",
"     <i>",
"      Haemophilus",
"     </i>",
"     b capsular polysaccharide 10 mcg [bound to tetanus toxoid 24 mcg] per 0.5 mL [contains sucrose; may be reconstituted with provided diluent (forms solution; contains natural rubber/natural latex in packaging)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hiberix&reg;:",
"     <i>",
"      Haemophilus",
"     </i>",
"     b capsular polysaccharide 10 mcg [bound to tetanus toxoid 25 mcg] per 0.5 mL (0.5 mL) [contains lactose 12.6 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PedvaxHIB&reg;:",
"     <i>",
"      Haemophilus",
"     </i>",
"     b capsular polysaccharide 7.5 mcg [bound to",
"     <i>",
"      Neisseria meningitidis",
"     </i>",
"     OMPC 125 mcg] per 0.5 mL (0.5 mL) [contains aluminum; natural rubber/natural latex in packaging]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well; administer I.M. in either the anterolateral aspect of the thigh or deltoid muscle of the arm;",
"     <b>",
"      not for I.V. or SubQ administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; protect from light (Hiberix&reg;). Once reconstituted with saline, store under refrigeration and use within 24 hours. ActHIB&reg;  reconstituted with Tripedia&reg; should be administered within 30 minutes. Hiberix&reg; saline diluent may be stored under refrigeration or at room temperature; do not freeze, discard diluent if frozen. Shake well before use. Discard any unused portion.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Routine, full series immunization of children 2 months to 5 years of age against invasive disease caused by",
"     <i>",
"      H. influenzae",
"     </i>",
"     (ActHIB&reg;: FDA approved in ages 2-18 months; PedvaxHIB&reg;: FDA approved in ages 2-71 months)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Routine booster only immunization of children (FDA approval: Hiberix&reg; in ages 15 months to 4 years)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of all children through age 59 months. Unimmunized children (&ge;5 years), adolescents, and adults with chronic conditions associated with an increased risk of",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type b disease (eg, splenectomies, sickle cell disease, leukemia, or HIV infection) should receive a single dose of Hib vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F178267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Crying (unusual, high pitched, prolonged), fever, fussiness, irritability, pain, restlessness, sleepiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Erythema, induration, pain, soreness, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions, anaphylactoid reactions, angioedema, apnea,  febrile seizure, Guillain-Barr&eacute; syndrome, hypersensitivity, hyporesponsive episodes, hypotonia, injection site abscess (sterile), lethargy, lymphadenopathy, malaise, mass, pneumonia, seizure, swelling (extensive) of the injected limb, syncope, urticaria, vasovagal response",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component including tetanus toxoid (ActHIB&reg;, Hiberix&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009). Use caution in patients with history of Guillain-Barr&eacute; syndrome (GBS) especially if occurred within 6 weeks following a prior",
"     <i>",
"      Haemophilus",
"     </i>",
"     b vaccine. Some products may contain lactose; some packaging may contain natural latex rubber.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactic/anaphylactoid reactions should be available during vaccine use. The carrier proteins used in Haemophilus b polyribosylribitol phosphate-outer membrane polysaccharide conjugate (PRP-T, ActHIB&reg;, Hiberix&reg;) are chemically and immunologically related to toxoids contained in DTaP vaccine. Earlier or simultaneous vaccination with tetanus toxoids may be required to elicit an optimal anti-PRP antibody response. In contrast, the immunogenicity of PedvaxHIB&reg; is not affected by vaccination with DTP. In infants in whom DTaP or DT vaccination is deferred, PedvaxHIB&reg; may be advantageous for",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type b vaccination. Immunization with ActHIB&reg; and Hiberix&reg; is not a substitute for routine tetanus immunization.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Children with chronic illness associated with increased risk of",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type b disease may have impaired anti-PRP antibody responses to conjugate vaccination. Examples include those with HIV infection, immunoglobulin deficiency, anatomic or functional asplenia, and sickle cell disease, as well as recipients of bone marrow transplants and recipients of chemotherapy for malignancy. Some children with immunologic impairment may benefit from more doses of conjugate vaccine than normally indicated. Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F178244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13929380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates production of anticapsular antibodies to provide active immunity to",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F9551033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If Hiberix&reg; is inadvertently administered during the primary vaccination series, the dose can be counted as a valid PRP-T dose that does not need repeated if administered according to schedule. In this case, a total of 3 doses completes the primary series.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38149/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      CDC Licensure of a Haemophilus influenzae Type b (Hib) Vaccine (Hiberix) and Updated Recommendations for Use of Hib Vaccine. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm?s_cid=mm5836a5_e\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm?s_cid=mm5836a5_e",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-15):1-48. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38149/abstract-text/17136024/pubmed\" id=\"17136024\" target=\"_blank\">",
"        17136024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommended Adult Immunization Schedule - United States, 2011,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2011, 60(4).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommended Immunization Schedules for Persons Aged 0-18 Years - United States, 2011,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2011, 60(5).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38149/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38149/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38149/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12933 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-00EEC62513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38149=[""].join("\n");
var outline_f37_16_38149=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178251\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178252\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059142\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059136\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178235\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178221\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059146\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059139\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059145\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178267\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059148\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059135\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059134\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299433\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178229\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178232\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178244\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929380\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059133\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9551033\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12933\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12933|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/14/230?source=related_link\">",
"      Haemophilus influenzae type b conjugate vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/32/14849?source=related_link\">",
"      Haemophilus influenzae type b conjugate vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_16_38150="CT scan peritoneal perforation of the gallbladder fundus";
var content_f37_16_38150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Contained gallbladder perforation in a patient with acute cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic (CT) scan showing a sealed perforation of the gallbladder. Transverse (A) and reformatted coronal projections (B) of the CT scan demonstrate a focal accumulation of fluid near the fundus of the gallbladder (white arrowhead) with significant induration in the pericholecystic fat (yellow arrow). At surgery a necrotic and perforated gallbladder was identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38150=[""].join("\n");
var outline_f37_16_38150=null;
var title_f37_16_38151="ACTH deficiency in survivors of childhood cancer";
var content_f37_16_38151=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ACTH deficiency in survivors of childhood cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/16/38151/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38151/contributors\">",
"     Susan R Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/16/38151/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38151/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38151/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/16/38151/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38151/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/16/38151/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing numbers of children and adults are survivors of childhood cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. One estimate suggests that one in every 900 individuals between the ages of 15 and 45 years has experienced and survived cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/2\">",
"     2",
"    </a>",
"    ]. These survivors are subject to long-term complications of tumor or tumor therapy, including endocrinologic abnormalities.",
"   </p>",
"   <p>",
"    The most common endocrinologic abnormalities in survivors of childhood cancer are growth hormone (GH) deficiency and hypothyroidism (either central or primary). The next most common are alterations of pubertal timing (early, rapid, or precocious puberty; delayed or absent puberty). Adrenocorticotropin (ACTH) deficiency, less common than these disorders, has more serious consequences if it is not detected.",
"   </p>",
"   <p>",
"    The normal regulation of cortisol secretion and the clinical manifestations, diagnosis, and treatment of ACTH deficiency in childhood cancer survivors are reviewed here. Growth hormone deficiency, hypothyroidism, and pubertal abnormalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7401?source=see_link\">",
"     \"Pubertal development and gonadal function in survivors of childhood cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenocorticotropin (ACTH) deficiency should be suspected in patients who have a history of brain tumor (regardless of therapy modality) or cranial irradiation, and those who have growth hormone deficiency, central hypothyroidism, or diabetes insipidus. Prospective surveillance for development of ACTH deficiency in these patients must continue for 10 to 15 years after radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Surveillance should include the yearly measurement of an 8 AM cortisol and or a low-dose ACTH test if the 8 AM cortisol is below 18",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (497",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    ACTH deficiency occurs in less than 3 percent of patients after chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/6\">",
"     6",
"    </a>",
"    ]. It also occurs uncommonly in patients who have received intracranial radiation if the cumulative cranial radiation dose did not exceed 24 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Reports of incidence in cancer survivors vary according to patient age, tumor location, radiation dose, and duration after tumor therapy. Reported incidence of ACTH deficiency ranges from 12 percent more than 10 years after posterior fossa tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/4,5,10\">",
"     4,5,10",
"    </a>",
"    ], 20 percent even before irradiation for brain tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/11\">",
"     11",
"    </a>",
"    ], to about 25 percent of slowly growing children after any brain tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/3,12\">",
"     3,12",
"    </a>",
"    ], and 27 percent after surgery for hypothalamic tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/13\">",
"     13",
"    </a>",
"    ] ACTH deficiency was identified in 21 percent of adults after cranial irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/14\">",
"     14",
"    </a>",
"    ]. After an average radiation dose of 42Gy for medulloblastoma or primitive neuroectodermal tumor, 38 percent of children developed ACTH deficiency by four years, and 55 percent by six years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the healthy individual with no injury to the endocrine system, hypothalamic corticotrophin-releasing hormone (CRH) and vasopressin released in two or three synchronous pulses per hour synergistically stimulate secretion of adrenocorticotropin (ACTH) from the pituitary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/16\">",
"     16",
"    </a>",
"    ]. ACTH secretion is pulsatile (",
"    <a class=\"graphic graphic_figure graphicRef57231 \" href=\"mobipreview.htm?6/17/6431\">",
"     figure 1",
"    </a>",
"    ), varies throughout the day, increases with stress, and is negatively inhibited by glucocorticoids. Because cortisol secretion is regulated by ACTH, cortisol secretion has similar characteristics (",
"    <a class=\"graphic graphic_figure graphicRef61069 \" href=\"mobipreview.htm?36/46/37614\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of adrenal insufficiency can be subtle (",
"    <a class=\"graphic graphic_table graphicRef57534 \" href=\"mobipreview.htm?30/43/31420\">",
"     table 1",
"    </a>",
"    ). They include poor weight gain, anorexia, easy fatigability, and poor stamina. These symptoms may be expected in a child who is being treated for cancer or recovering from cancer therapy. Thus, a normal review of systems cannot exclude adrenocorticotropin (ACTH) deficiency. Overt manifestations of ACTH deficiency include weight loss, shakiness that is relieved by eating, and hypoglycemia. Signs of adrenal crisis are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef78490 \" href=\"mobipreview.htm?3/53/3931\">",
"     table 2",
"    </a>",
"    ). In patients who have ACTH deficiency, as opposed to primary adrenal insufficiency, salt craving, electrolyte imbalance, vitiligo, and hyperpigmentation usually are not observed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with partial ACTH deficiency may have only subtle symptoms unless they become ill. Illness can disrupt their usual homeostasis, causing them to have a more severe, prolonged, or complicated course than expected. They can be slow to awaken from anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/4\">",
"     4",
"    </a>",
"    ]. Similar to complete ACTH deficiency, incomplete or unrecognized ACTH deficiency can be life-threatening during concurrent illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms related to cortisol deficiency can be caused by adrenocorticotropin (ACTH) deficiency or by primary adrenal insufficiency (eg, direct injury to the adrenal glands).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ACTH deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACTH deficiency occurs in survivors of childhood cancer as the result of tumor or therapy-induced injury to the hypothalamic pituitary axis. Reduced ACTH secretion decreases the synthesis of cortisol and androgens. Mineralocorticoids are not affected; serum sodium and potassium concentrations are typically normal, but may be decreased slightly because of indirect effects on renal free water clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Primary adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary adrenal insufficiency is extremely rare in survivors of childhood cancer, perhaps occurring only after radiation therapy directed at the adrenal glands or after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    chemotherapy for adrenal carcinoma. Patients with primary adrenal insufficiency have manifestations of both glucocorticoid and mineralocorticoid deficiency. They have low serum sodium, elevated serum potassium, and elevated serum renin and ACTH concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of adrenocorticotropin (ACTH) deficiency is made in the laboratory; certain clinical features may suggest the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef57534 \" href=\"mobipreview.htm?30/43/31420\">",
"     table 1",
"    </a>",
"    ), but their absence cannot exclude it. Confirmation of the diagnosis of adrenal insufficiency entails demonstration of inappropriately low cortisol secretion and determination of whether the cortisol deficiency is caused by primary adrenal disease or pituitary hypofunction (ACTH deficiency) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal evaluation for ACTH deficiency is controversial and should be directed by an endocrinologist. Although the history may provide clues to the site of possible adrenal deficiency, measurement of plasma ACTH and the responses of the anterior pituitary gland and adrenal cortex to a variety of stimuli will confirm the diagnosis and define the site at which the defect exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ACTH concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the basal plasma ACTH concentration usually can distinguish between primary adrenal disease and ACTH deficiency if the reference laboratory's ACTH assay is reliable and there is no urgency in establishing the cause of adrenal insufficiency.",
"   </p>",
"   <p>",
"    In primary adrenal insufficiency, the 8 AM plasma ACTH concentration is high, sometimes as high as or higher than 4000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (880",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"    In contrast, plasma ACTH concentrations are low or low normal in secondary or tertiary adrenal insufficiency. The normal value at 8 AM is usually between 20 and 80",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (4.5 and 18",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40246?source=see_link\">",
"     \"Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach is somewhat different in patients who present in hypotensive crisis. These patients may have adrenal insufficiency or one of several other possible diagnoses. Furthermore, adrenal insufficiency, if present, may have been caused by infection, a bleeding diathesis, or metastatic disease that requires prompt diagnosis and treatment. In these patients, measurement of basal serum cortisol followed by the low-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/45/29397?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    (see below) provides the most rapid and reliable diagnosis. A basal plasma ACTH measurement can be ordered at the same time, but diagnosis and treatment must proceed immediately without waiting for the plasma ACTH result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Adrenal crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stimulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to measurement of ACTH concentrations, measurement of the response of the anterior pituitary gland and adrenal cortex to a variety of stimuli (eg, ACTH,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43219?source=see_link\">",
"     metyrapone",
"    </a>",
"    -induced hypocortisolemia, and insulin-induced hypoglycemia) can confirm the diagnosis.",
"   </p>",
"   <p>",
"    The \"gold standard\" for diagnosis of ACTH deficiency has been failure to raise serum cortisol above 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (552",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in response to insulin-induced or spontaneous hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     Glucagon",
"    </a>",
"    can alternatively be used to stimulate both growth hormone and the ACTH-cortisol response in the same test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/4,21,22\">",
"     4,21,22",
"    </a>",
"    ]. Another method of diagnosis involves the administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43219?source=see_link\">",
"     metyrapone",
"    </a>",
"    to block the adrenal conversion of 11-deoxycortisol to cortisol. This stimulates increased production of ACTH and a secondary increase of 11-deoxycortisol (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"mobipreview.htm?0/7/123\">",
"     figure 3",
"    </a>",
"    ). Failure to raise 11-deoxycortisol above 7",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in the presence of a low serum cortisol (below 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [138",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    signifies ACTH deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/20,23,24\">",
"     20,23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16135?source=see_link\">",
"     \"Metyrapone stimulation tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An attempt to simplify evaluation of the hypothalamic-pituitary-adrenal axis led to development of the one-hour ACTH test (or high-dose ACTH test), which consists of the administration of ACTH (250",
"    <span class=\"nowrap\">",
"     mcg/m2)",
"    </span>",
"    by intravenous infusion over one minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/20,25-27\">",
"     20,25-27",
"    </a>",
"    ]. Serum cortisol is measured one hour later and is normally greater than 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (552",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    Patients with complete ACTH deficiency (in whom the adrenal gland has not been exposed to ACTH for 4 to 10 weeks) fail to respond with a one-hour serum cortisol &gt;20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (552",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast, patients with partial ACTH deficiency or recent onset of complete ACTH deficiency may have a normal serum cortisol response to this dose of ACTH and may not be detected by this test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/17,26,28,29\">",
"     17,26,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The low-dose ACTH test is the most sensitive test for partial ACTH deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/26,28-33\">",
"     26,28-33",
"    </a>",
"    ]. In this test, a more physiologic dose of ACTH (1",
"    <span class=\"nowrap\">",
"     mcg/m2)",
"    </span>",
"    is administered by intravenous infusion over one minute and blood for serum cortisol assay is drawn 20 minutes after injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/30,33\">",
"     30,33",
"    </a>",
"    ]. Peak serum cortisol &gt;20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (552",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    is considered normal and peak serum cortisol &lt;18",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (497",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with cortisol peaks of 18 to 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (497 to 552",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    have indeterminate results; they should be treated with glucocorticoid during illness and require further evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/26\">",
"     26",
"    </a>",
"    ]. Further evaluation can include a second low-dose ACTH test or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43219?source=see_link\">",
"     metyrapone",
"    </a>",
"    at two months to one year later. One series found no evidence of neurosecretory ACTH dysfunction in patients with fatigue but normal response to cortisol stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16135?source=see_link\">",
"     \"Metyrapone stimulation tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The low-dose and high-dose ACTH stimulation tests have supplanted insulin-induced hypoglycemia in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/34\">",
"     34",
"    </a>",
"    ]. The results are similar to those obtained with insulin-induced hypoglycemia. In addition, ACTH tests can be performed without a clinician being present and are less expensive. However, no single test is 100 percent \"reliable for establishing or excluding the presence of secondary or tertiary adrenal insufficiency\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/4\">",
"     4",
"    </a>",
"    ]. The practitioner must continue to use clinical judgment in the diagnosis and management of a child suspected of having ACTH deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals diagnosed with adrenal insufficiency require daily",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    replacement, divided into two or three doses per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, they must receive additional glucocorticoid during times of illness or stress (eg, fever, gastrointestinal illness, injury) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Hydrocortisone is the preferred agent for glucocorticoid replacement in children because it is least likely to impair growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    for replacement therapy is 7 to 10",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day, divided into two or three doses administered by mouth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. As examples, a child whose body surface is 0.9 m2 could receive 2.5 mg three times per day or an adult whose body surface is 1.5 m2 could receive 5 mg at breakfast and at 3 PM, plus 2.5 mg at bedtime.",
"   </p>",
"   <p>",
"    The glucocorticoid dose may need to be increased in patients taking drugs that accelerate hepatic steroid metabolism, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , barbiturates,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    , and aminoglutethimide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with growth hormone deficiency who have partial or total adrenocorticotropin (ACTH) deficiency and are receiving suboptimal cortisol or cortisone replacement may be at risk of developing symptoms of cortisol deficiency when growth hormone therapy is initiated. This is because of the inhibitory effect of growth hormone on 11-beta-hydroxysteroid dehydrogenase type 1, the enzyme that converts cortisone to cortisol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/42\">",
"     42",
"    </a>",
"    ]. This effect of growth hormone was not observed in children with idiopathic isolated growth hormone deficiency, but might be more common with organic etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/43\">",
"     43",
"    </a>",
"    ]. Similarly, the initiation of thyroid hormone therapy in a child with unrecognized or undertreated ACTH deficiency also can precipitate adrenal crisis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ACTH deficiency do not need mineralocorticoid replacement because these hormones are produced by the adrenal gland under the influence of the renin-aldosterone system, rather than by stimulated by ACTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stress therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of additional",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    that is necessary during times of illness is 30",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day divided into three doses administered by mouth. Patients whose illness or injury is severe enough to require emergency care or hospitalization, who are unable to retain oral medication, or who require anesthesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery should urgently receive hydrocortisone 100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    IM or IV, followed by hydrocortisone 10 to 25",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    IV every six hours during management of the critical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients and families should be instructed regarding the proper \"stress\" dose for their weight and should keep an emergency supply (see below).",
"   </p>",
"   <p>",
"    In critical illness such as septic shock, there may be transient adrenal insufficiency. Blood pressure may benefit from stress steroid therapy if serum cortisol during such severe illness is below 25",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (690",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38151/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At stress doses,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    provides some mineralocorticoid effect. The hydrocortisone dose should be reduced to the usual replacement therapy dose as soon as the event is over or the patient's medical status improves. Tapering of the dose is not necessary if the pharmacologic stress doses are used for less than 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient and family education is an important component of management of patients with ACTH deficiency. The patient and responsible family members should be instructed about:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The nature of the hormonal deficit and the rationale for replacement therapy",
"     </li>",
"     <li>",
"      Maintenance medications and the need for changes in medications during minor illnesses",
"     </li>",
"     <li>",
"      When to consult a clinician",
"     </li>",
"     <li>",
"      When and how to inject glucocorticoids for emergencies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Every patient should have several pre-prepared syringes of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (Solu-Cortef&reg;): one at home, one at work or school, and one in the car. In addition, it is wise for the patient to carry such a syringe at all times. The syringes can be obtained as 100",
"    <span class=\"nowrap\">",
"     mg/2mL",
"    </span>",
"    activials, 250",
"    <span class=\"nowrap\">",
"     mg/2",
"    </span>",
"    mL vials, or can be prepared by the pharmacist in regular 1 mL syringes from a multidose vial. The patient and parents must be instructed regarding the correct dose. The injectable stress dose is 10 times the daily hydrocortisone dose. Thus, typical doses for children would be 50 mg (1.0 mL of the activial) to 125 mg (0.4 to 1.0 mL of a 250",
"    <span class=\"nowrap\">",
"     mg/2",
"    </span>",
"    mL solution). Unused syringes should be replaced each year or if the solution becomes cloudy or colored.",
"   </p>",
"   <p>",
"    The patient and one or more responsible family or household members should be instructed to inject the contents of a syringe subcutaneously or intramuscularly anywhere on the patient's body in any of the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient has a major injury with substantial blood loss (more than one cup), fracture, or neurogenic shock",
"     </li>",
"     <li>",
"      The patient has nausea and vomiting and cannot retain oral medications",
"     </li>",
"     <li>",
"      The patient has symptoms of acute adrenal insufficiency",
"     </li>",
"     <li>",
"      The patient is found unresponsive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Instructions should include the need to obtain, or be brought to, medical help",
"    <strong>",
"     immediately",
"    </strong>",
"    after the injection. The patient should be instructed to have a low threshold for injecting the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    : if it might be necessary, it should be injected and medical attention should be sought. It is unlikely, however, that a patient will need the stress dose of hydrocortisone more than two or three times a year, and most patients go for years without doing so. Used hydrocortisone syringes should be replaced immediately.",
"   </p>",
"   <p>",
"    Every patient should wear a medical alert (Medic Alert&reg;) bracelet or necklace and carry the Emergency Medical Information Card that is supplied with it. Both should indicate the diagnosis, the daily medications and doses, and the clinician to call in the event of an emergency. Patients can enroll in Medic Alert&reg; by calling 800-432-5372 or through the internet at",
"    <a class=\"external\" href=\"file://www.medicalert.org/\">",
"     www.medicalert.org",
"    </a>",
"    (United States) and",
"    <a class=\"external\" href=\"file://www.medicalert.ca/\">",
"     www.medicalert.ca/",
"    </a>",
"    (Canada).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenocorticotropin (ACTH) deficiency is an uncommon but serious complication of childhood cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACTH deficiency should be suspected in patients who have a history of brain tumor or cranial irradiation, and those who have growth hormone deficiency, central hypothyroidism, or diabetes insipidus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of ACTH varies depending on patient age, tumor location, radiation dose, and duration after tumor therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of adrenal insufficiency can be subtle and nonspecific, and include poor weight gain, anorexia, easy fatigability, and poor stamina (",
"      <a class=\"graphic graphic_table graphicRef57534 \" href=\"mobipreview.htm?30/43/31420\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ACTH deficiency is made by laboratory testing that demonstrates inappropriately low cortisol secretion and determination of whether the cortisol deficiency is caused by primary adrenal disease or hypothalamic-pituitary hypofunction. Measurement of plasma ACTH and the responses of the anterior pituitary gland and adrenal cortex to a variety of stimuli will confirm the diagnosis and define the site at which the defect exists. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest replacement with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (dose of 7 to 10",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day) in two or three divided doses as the glucocorticoid of choice for the management of chronic adrenal insufficiency (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other glucocorticoid agents may be used, but hydrocortisone is the preferred agent because it is least likely to impair growth. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dose of glucocorticoids should be increased during times of illness or injury. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Stress therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient and family education is an important component of management of patients with ACTH deficiency. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Patient education'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/1\">",
"      Hudson MM, Jones D, Boyett J, et al. Late mortality of long-term survivors of childhood cancer. J Clin Oncol 1997; 15:2205.",
"     </a>",
"    </li>",
"    <li>",
"     Miller BA, Ries LA, Hankey BF, et al. SEER Cancer Statistics Review: 1973-1990. NIH Publication no. 93-2789. National Cancer Institute; Bethesda, MD 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/3\">",
"      Rose SR, Danish RK, Kearney NS, et al. ACTH deficiency in childhood cancer survivors. Pediatr Blood Cancer 2005; 45:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/4\">",
"      Hameed R, Zacharin MR. Long-term endocrine effects of cancer treatment: experience of the Royal Children's Hospital, Melbourne. J Paediatr Child Health 2005; 41:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/5\">",
"      Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, et al. Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor. J Clin Endocrinol Metab 2003; 88:3149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/6\">",
"      Rose SR, Schreiber RE, Kearney NS, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/7\">",
"      Rose SR, Lustig RH, Pitukcheewanont P, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 1999; 84:4472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/8\">",
"      Darzy KH, Shalet SM. Absence of adrenocorticotropin (ACTH) neurosecretory dysfunction but increased cortisol concentrations and production rates in ACTH-replete adult cancer survivors after cranial irradiation for nonpituitary brain tumors. J Clin Endocrinol Metab 2005; 90:5217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/9\">",
"      Darzy KH, Shalet SM. Hypopituitarism following Radiotherapy Revisited. Endocr Dev 2009; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/10\">",
"      Spoudeas HA, Charmandari E, Brook CG. Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Med Pediatr Oncol 2003; 40:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/11\">",
"      Merchant TE, Williams T, Smith JM, et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncol Biol Phys 2002; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/12\">",
"      Rohrer TR, Beck JD, Grabenbauer GG, et al. Late endocrine sequelae after radiotherapy of pediatric brain tumors are independent of tumor location. J Endocrinol Invest 2009; 32:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/13\">",
"      Brauner R, Trivin C, Zerah M, et al. Diencephalic syndrome due to hypothalamic tumor: a model of the relationship between weight and puberty onset. J Clin Endocrinol Metab 2006; 91:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/14\">",
"      Agha A, Sherlock M, Brennan S, et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab 2005; 90:6355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/15\">",
"      Laughton SJ, Merchant TE, Sklar CA, et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 2008; 26:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/16\">",
"      Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/17\">",
"      Streeten DH, Anderson GH Jr, Bonaventura MM. The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test. J Clin Endocrinol Metab 1996; 81:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/18\">",
"      Yanovski JA. Anesthesia in patients with adrenal disorders. Anesthesia Today 1997; 8:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/19\">",
"      Oelkers W. Adrenal insufficiency. N Engl J Med 1996; 335:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/20\">",
"      Steiner H, B&auml;hr V, Exner P, Oelkers PW. Pituitary function tests: comparison of ACTH and 11-deoxy-cortisol responses in the metyrapone test and with the insulin hypoglycemia test. Exp Clin Endocrinol 1994; 102:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/21\">",
"      B&ouml;ttner A, Kratzsch J, Liebermann S, et al. Comparison of adrenal function tests in children--the glucagon stimulation test allows the simultaneous assessment of adrenal function and growth hormone response in children. J Pediatr Endocrinol Metab 2005; 18:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/22\">",
"      Kappy MS, Drake A, Gao D, Ratliff R. Assessing adrenal function in primary care settings with a single sample subcutaneous glucagon test. J Pediatr 2006; 149:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/23\">",
"      Sch&ouml;nesh&ouml;fer M, L'age M, Oelkers W. Short time kinetics of deoxycorticosterone, deoxycortisol, corticosterone and cortisol during single dose metyrapone test. Acta Endocrinol (Copenh) 1977; 85:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/24\">",
"      Shankar RR, Jakacki RI, Haider A, et al. Testing the hypothalamic-pituitary-adrenal axis in survivors of childhood brain and skull-based tumors. J Clin Endocrinol Metab 1997; 82:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/25\">",
"      Clayton RN. Short Synacthen test versus insulin stress test for assessment of the hypothalamo [correction of hypothalmo]-pituitary--adrenal axis: controversy revisited. Clin Endocrinol (Oxf) 1996; 44:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/26\">",
"      Rose SR, Lustig RH, Burstein S, et al. Diagnosis of ACTH deficiency. Comparison of overnight metyrapone test to either low-dose or high-dose ACTH test. Horm Res 1999; 52:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/27\">",
"      Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med 2003; 139:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/28\">",
"      Soule SG, Fahie-Wilson M, Tomlinson S. Failure of the short ACTH test to unequivocally diagnose long-standing symptomatic secondary hypoadrenalism. Clin Endocrinol (Oxf) 1996; 44:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/29\">",
"      Dickstein G, Arad E, Shechner C. Low-dose ACTH stimulation test. Endocrinologist 1997; 7:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/30\">",
"      Dickstein G, Shechner C, Nicholson WE, et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab 1991; 72:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/31\">",
"      Agwu JC, Spoudeas H, Hindmarsh PC, et al. Tests of adrenal insufficiency. Arch Dis Child 1999; 80:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/32\">",
"      Tordjman K, Jaffe A, Grazas N, et al. The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases. J Clin Endocrinol Metab 1995; 80:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/33\">",
"      Graybeal ML, Fang VS. Physiological dosing of exogenous ACTH. Acta Endocrinol (Copenh) 1985; 108:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/34\">",
"      Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab 2008; 93:4245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/35\">",
"      Maghnie M, Uga E, Temporini F, et al. Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic-pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests. Eur J Endocrinol 2005; 152:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/36\">",
"      Maguire AM, Ambler GR, Moore B, et al. Prolonged hypocortisolemia in hydrocortisone replacement regimens in adrenocorticotrophic hormone deficiency. Pediatrics 2007; 120:e164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/37\">",
"      Linder BL, Esteban NV, Yergey AL, et al. Cortisol production rate in childhood and adolescence. J Pediatr 1990; 117:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/38\">",
"      Elias AN, Gwinup G. Effects of some clinically encountered drugs on steroid synthesis and degradation. Metabolism 1980; 29:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/39\">",
"      Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984; 59:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/40\">",
"      Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/41\">",
"      Santen RJ, Lipton A, Kendall J. Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism. JAMA 1974; 230:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/42\">",
"      Toogood AA, Taylor NF, Shalet SM, Monson JP. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J Clin Endocrinol Metab 2000; 85:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/43\">",
"      Giavoli C, Bergamaschi S, Ferrante E, et al. Effect of growth hormone deficiency and recombinant hGH (rhGH) replacement on the hypothalamic-pituitary-adrenal axis in children with idiopathic isolated GH deficiency. Clin Endocrinol (Oxf) 2008; 68:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/44\">",
"      Kozyra EF, Wax RS, Burry LD. Can 1 microg of cosyntropin be used to evaluate adrenal insufficiency in critically ill patients? Ann Pharmacother 2005; 39:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38151/abstract/45\">",
"      Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6241 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38151=[""].join("\n");
var outline_f37_16_38151=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ACTH deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Primary adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACTH concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stimulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stress therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6241|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/17/6431\" title=\"figure 1\">",
"      Circadian rhythm of plasma ACTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/46/37614\" title=\"figure 2\">",
"      Circadian rhythm in serum cortisol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/7/123\" title=\"figure 3\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/43/31420\" title=\"table 1\">",
"      Signs of adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3931\" title=\"table 2\">",
"      Signs of adrenal crisis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31607?source=related_link\">",
"      Growth failure after childhood cancer: Role of growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=related_link\">",
"      Growth failure after childhood cancer: Role of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40246?source=related_link\">",
"      Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16135?source=related_link\">",
"      Metyrapone stimulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7401?source=related_link\">",
"      Pubertal development and gonadal function in survivors of childhood cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_16_38152="Citalopram: Pediatric drug information";
var content_f37_16_38152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Citalopram: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"    see \"Citalopram: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/49/12054?source=see_link\">",
"    see \"Citalopram: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CeleXA&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Citalopram&reg;;",
"     </li>",
"     <li>",
"      Auro-Citalopram;",
"     </li>",
"     <li>",
"      Ava-Citalopram;",
"     </li>",
"     <li>",
"      Celexa&reg;;",
"     </li>",
"     <li>",
"      Citalopram-Odan;",
"     </li>",
"     <li>",
"      CO Citalopram;",
"     </li>",
"     <li>",
"      CTP 30;",
"     </li>",
"     <li>",
"      Dom-Citalopram;",
"     </li>",
"     <li>",
"      JAMP-Citalopram;",
"     </li>",
"     <li>",
"      Manda-Citalopram;",
"     </li>",
"     <li>",
"      Mint-Citalopram;",
"     </li>",
"     <li>",
"      Mylan-Citalopram;",
"     </li>",
"     <li>",
"      PHL-Citalopram;",
"     </li>",
"     <li>",
"      PMS-Citalopram;",
"     </li>",
"     <li>",
"      Q-Citalopram;",
"     </li>",
"     <li>",
"      RAN&trade;-Citalo;",
"     </li>",
"     <li>",
"      ratio-Citalopram;",
"     </li>",
"     <li>",
"      Riva-Citalopram;",
"     </li>",
"     <li>",
"      Sandoz-Citalopram;",
"     </li>",
"     <li>",
"      Septa-Citalopram;",
"     </li>",
"     <li>",
"      Teva-Citalopram",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1005975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1006010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"      see \"Citalopram: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Slower titration of dose every 2-4 weeks may minimize risk of SSRI associated behavioral activation, which has been shown to increase risk of suicidal behavior. Doses &gt;40 mg are not recommended due to risk of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Depression:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Not FDA approved. Limited information is available; only one randomized, placebo controlled trial has shown citalopram to be effective for the treatment of depression in pediatric patients (Wagner, 2004); other controlled pediatric trials have",
"     <b>",
"      not",
"     </b>",
"     shown benefit (Sharp, 2006; von Knorring, 2006; Wagner, 2005). Some experts recommend the following doses (Dopheide, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &le;11 years: Initial: 10 mg/day given once daily; increase dose slowly by 5 mg/day every 2 weeks as clinically needed; dosage range: 20-40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents &ge;12 years: Initial: 20 mg/day given once daily; increase dose slowly by 10 mg/day every 2 weeks as clinically needed; dosage range: 20-40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Obsessive-compulsive disorder:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Not FDA approved. Limited information is available; several open label trials have been published (Mukaddes, 2003; Thomsen, 1997; Thomsen, 2001). Some experts recommend the following doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &le;11 years: Initial: 5-10 mg/day given once daily; increase dose slowly by 5 mg/day every 2 weeks as clinically needed; dosage range: 10-40 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents &ge;12 years: Initial: 10-20 mg/day given once daily; increase dose slowly by 10 mg/day every 2 weeks as clinically needed; dosage range: 10-40 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Higher mg/kg doses are needed in children compared to adolescents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Depression:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients &lt;60 years: Initial: 20 mg once daily; may increase dose in 20 mg increments at intervals of &ge;1 week up to a maximum daily dose: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients &ge;60 years, poor metabolizers of CYP2C19",
"     <b>",
"      or",
"     </b>",
"     concurrent use of moderate to strong CYP2C19 inhibitors (eg, cimetidine): 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild or moderate renal impairment: No dosage adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute): Use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Adults: 20 mg once daily due to increased serum concentrations and the risk of QT prolongation",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 10 mg/5 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CeleXA&reg;: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CeleXA&reg;: 20 mg, 40 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088568.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088568.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4417658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1005999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1005976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression (FDA approved in adults); has also been used to treat obsessive-compulsive disorder (OCD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CeleXA&reg; may be confused with CeleBREX&reg;, Cerebyx&reg;, Ranexa&trade;, ZyPREXA&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F152033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, orthostatic hypotension, QT prolongation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, amnesia, anorexia, anxiety, apathy, concentration impaired, confusion, depression, fatigue (dose related), fever, insomnia (dose related), migraine, somnolence (dose related), suicide attempt, yawning (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, dysmenorrhea, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased, diarrhea, dyspepsia, flatulence, nausea, salivation increased, taste perversion, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculation disorder, impotence (dose related), polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal accommodation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, alopecia, anaphylaxis, anemia, angina pectoris, angioedema, arthritis, asthma, atrial fibrillation, bronchitis, bundle branch block, bursitis, cardiac arrest, cardiac failure, cataracts, catatonia, cerebrovascular accident, cholelithiasis, delirium, delusions, dependence, depersonalization, diplopia, diverticulitis, duodenal ulcer, eczema, epidermal necrolysis, erythema multiforme, extrapyramidal symptoms, extrasystoles, galactorrhea, gastric ulcer, gastrointestinal hemorrhage, glaucoma, granulocytopenia, gynecomastia, hallucinations, hemolytic anemia, hepatic necrosis, hepatitis, hyperpigmentation, hypertension, hypertrichosis, hypoglycemia, hypokalemia, hyponatremia, hypothyroidism, leukocytosis, leukopenia, lymphadenopathy, lymphocytosis, lymphopenia, muscle weakness, myocardial infarction, myocardial ischemia, neuroleptic malignant syndrome, obesity, osteoporosis, pancreatitis, phlebitis, photosensitivity, pneumonia, priapism, prolactinemia, prothrombin decreased, psoriasis, psychosis, ptosis, pulmonary embolism, renal calculi, renal failure, rhabdomyolysis, seizures, serotonin syndrome, SIADH, spontaneous abortion, syncope, thrombocytopenia, thrombosis, torsade de pointes, transient ischemic attack, urinary incontinence, urinary retention, vaginal bleeding, ventricular arrhythmia, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1005983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to citalopram or any component; use with MAO inhibitors within 14 days (potentially fatal reactions may occur); concurrent use of pimozide",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4005931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Citalopram may impair platelet aggregation and cause abnormal bleeding (eg, ecchymosis, purpura, upper GI bleeding); risk may be increased in patients with impaired platelet aggregation and with concurrent use of aspirin, NSAIDs, warfarin, or other drugs that affect coagulation; bleeding related to SSRI or SNRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage. Citalopram may impair cognitive or motor performance. Use with caution in patients with seizure disorders, concomitant illnesses that may effect hepatic metabolism or hemodynamic responses (eg, unstable cardiac disease, recent MI), and in suicidal patients; use with caution and decrease dose in patients with hepatic dysfunction; use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution during third trimester of pregnancy [newborns may experience adverse effects or withdrawal symptoms (consider risk and benefits); exposure to SSRIs late in pregnancy may also be associated with an increased risk for persistent pulmonary hypertension of the newborn (Chambers, 2006)]; high doses of citalopram have been associated with teratogenicity in animals. Use with caution in patients receiving diuretics or those who are volume depleted (may cause hyponatremia or SIADH). SSRI-associated vomiting is two- to threefold more prevalent in children compared to adolescents and is more prevalent in adolescents compared to adults (Safer, 2006). No clinical studies have assessed the combined use of citalopram and electroconvulsive therapy; however, use with caution in patients receiving electroconvulsive therapy; may increase the risks associated with electroconvulsive therapy, consider discontinuing, when possible, prior to electroconvulsive therapy treatment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1005984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy. Selective serotonin reuptake inhibitor (SSRI)-associated behavioral activation (ie, restlessness, hyperkinesis, hyperactivity, agitation) is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults. Somnolence (including sedation and drowsiness) is more common in adults compared to children and adolescents (Safer, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Avoid abrupt discontinuation; withdrawal syndrome with discontinuation symptoms (including agitation, dysphoria, anxiety, confusion, dizziness, hypomania, nightmares, irritability, sensory disturbances, headache, lethargy, emotional lability, insomnia, tinnitus, and seizures) may occur if therapy is abruptly discontinued or dose reduced; taper the dose to minimize risks of discontinuation symptoms. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, consider resuming the previous dose with a more gradual taper. To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. Citalopram is not FDA approved for the treatment of bipolar depression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Citalopram use may result in a dose-dependent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, which may be associated with torsade de pointes, ventricular tachycardia, or sudden death. Citalopram is not recommended in patients with congenital long QT syndrome, certain conditions (eg, bradycardia, heart failure, or recent acute MI), with concomitant medications which prolong the QT interval, or conditions that cause hypokalemia and/or hypomagnesemia; electrolyte and/or more frequent ECG monitoring is recommended if citalopram use is essential. Avoid doses &gt;40 mg/day due to increased risk of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation; higher doses have also not been shown to be more effective in treating depression in clinical trials. Citalopram should be discontinued in patients with a persistent QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec. Patients experiencing symptoms of cardiac arrhythmias (dizziness, palpitations, or syncope) should be evaluated further including cardiac monitoring.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Potentially fatal serotonin syndrome (SS) or neuroleptic malignant syndrome (NMS)-like reactions have occurred with SSRIs and serotonin/norepinephrine reuptake inhibitors (SNRIs) when used alone and particularly when used in combination with serotonergic drugs (eg, triptans), drugs that impair the metabolism of serotonin (eg, MAO inhibitors, linezolid), or antidopaminergic agents (eg, antipsychotics). Identification and differentiation of SS (eg, tremor, myoclonus, agitation) and more severe NMS-like reactions (eg, hyperthermia, muscle rigidity, autonomic instability, mental status changes) can be complex; monitor patients closely for either syndrome. Discontinue treatment (and any concomitant serotonergic and/or antidopaminergic agents) immediately if signs or symptoms arise and initiate supportive symptomatic therapy. Tryptophan (which can be metabolized to serotonin) and the herbal medicine St John's wort (",
"     <i>",
"      Hypericum perforatum",
"     </i>",
"     ) may increase serious side effects. Concomitant use of other SSRIs, SNRIs or tryptophan with citalopram is not recommended. Concurrent use or use within 2 weeks of discontinuing MAO inhibitors is contraindicated. In addition, allow at least 14 days after stopping citalopram before starting an MAO inhibitor.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F152019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (weak), CYP2C19 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a strong CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Citalopram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4417619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption is not affected by food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan supplements may increase serious side effects; its use is",
"     <b>",
"      not recommended",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F151954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F151968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Citalopram and its metabolites cross the human placenta. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of citalopram or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, women who are pregnant may require adjusted doses of citalopram to achieve euthymia. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1006017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG; electrolytes (potassium and magnesium concentrations); liver function tests and CBC with continued therapy; monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased). Monitor for anxiety, social functioning, mania, panic attacks; akathisia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1006001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A racemic bicyclic phthalane derivative, citalopram selectively inhibits serotonin reuptake in the presynaptic neurons and has minimal effects on norepinephrine or dopamine. Uptake inhibition of serotonin is primarily due to the S-enantiomer of citalopram. Displays little to no affinity for serotonin, dopamine, adrenergic, histamine, GABA, or muscarinic receptor subtypes.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4005932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Maximum effect: 8-12 weeks",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Duration: 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1006003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 12 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: &sim;80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic, primarily via CYP3A4 and CYP2C19; metabolized to N-demethylated, N-oxide, and deaminated metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 80%; tablets and oral solution are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: Range: 24-48 hours; mean: 35 hours (doubled with hepatic impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1 to 6 hours, average within 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (10% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Hepatic impairment: Decreased by 37%; Mild to moderate renal impairment: Decreased by 17%; Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute): No information available",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1006021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/49/12054?source=see_link\">",
"      see \"Citalopram: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of citalopram. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Avoid alcohol, caffeine, CNS stimulants, tryptophan supplements, and the herbal medicine St John's wort; avoid aspirin, NSAIDs, or other drugs that affect coagulation (may increase risks of bleeding); may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. Some medicines should not be taken with citalopram or should not be taken for a while after citalopram has been discontinued; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. It may take up to 4 weeks to see therapeutic effects from this medication. Take as directed; do not alter dose or frequency without consulting prescriber; avoid abrupt discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F4417659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If used for an extended period of time, long-term usefulness of citalopram should be periodically re-evaluated for the individual patient. A recent report describes 5 children (age: 8-15 years) who developed epistaxis (n=4) or bruising (n=1) while receiving SSRI therapy (sertraline) (Lake, 2000).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Neonates born to women receiving SSRIs later during the third trimester may experience respiratory distress, apnea, cyanosis, temperature instability, vomiting, feeding difficulty, hypoglycemia, constant crying, irritability, hypotonia, hypertonia, hyper-reflexia, tremor, jitteriness, and seizures; these symptoms may be due to a direct toxic effect, withdrawal syndrome, or (in some cases) serotonin syndrome. Withdrawal symptoms occur in 30% of neonates exposed to SSRIs",
"     <i>",
"      in utero",
"     </i>",
"     ; monitor newborns for at least 48 hours after birth; long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure to SSRIs are unknown (Levinson-Castiel, 2006).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bernard L, Stern R, Lew D, et al, &ldquo;Serotonin Syndrome After Concomitant Treatment With Linezolid and Citalopram,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(9):1197.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/12715317/pubmed\" id=\"12715317\" target=\"_blank\">",
"        12715317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lake MB, Birmaher B, Wassick S, et al, \"Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(1):35-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/10755580 /pubmed\" id=\"10755580 \" target=\"_blank\">",
"        10755580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levinson-Castiel R, Merlob P, Linder N, et al, \"Neonatal Abstinence Syndrome After",
"      <i>",
"       in utero",
"      </i>",
"      Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2006, 160(2):173-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/16461873/pubmed\" id=\"16461873\" target=\"_blank\">",
"        16461873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahlberg R, Kunz D, Sasse J, et al, &ldquo;Serotonin Syndrome With Tramadol and Citalopram,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2004, 161(6):1129.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/15169709/pubmed\" id=\"15169709\" target=\"_blank\">",
"        15169709",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mukaddes NM, Abali O, and Kaynak N, \"Citalopram Treatment of Children and Adolescents With Obsessive-Compulsive Disorder: A Preliminary Report,\"",
"      <i>",
"       Psychiatry Clin Neurosci",
"      </i>",
"      , 2003, 57(4):405-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/12839522/pubmed\" id=\"12839522\" target=\"_blank\">",
"        12839522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reinblatt SP and Riddle MA, \"Selective Serotonin Reuptake Inhibitors-Induced Apathy: A Pediatric Case Series,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 6(1/2):227-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/16553543/pubmed\" id=\"16553543\" target=\"_blank\">",
"        16553543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Safer DJ and Zito JM, \"Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(1/2):159-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/16553536 /pubmed\" id=\"16553536 \" target=\"_blank\">",
"        16553536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharp SC and Hellings JA, \"Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents: Practitioner Review,\"",
"      <i>",
"       Clin Drug Investig",
"      </i>",
"      , 2006, 26(5):247-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/17163258/pubmed\" id=\"17163258\" target=\"_blank\">",
"        17163258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tahir N, &ldquo;Serotonin Syndrome as a Consequence of Drug-Resistant Infections: An Interaction Between Linezolid and Citalopram,\"",
"      <i>",
"       J Am Med Dir Assoc",
"      </i>",
"      , 2004, 5(2):111-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/14984623/pubmed\" id=\"14984623\" target=\"_blank\">",
"        14984623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomsen PH, &ldquo;Child and Adolescent Obsessive-Compulsive Disorder Treated With Citalopram: Findings From an Open Trial of 23 Cases,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1997, 7(3):157-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/9466233 /pubmed\" id=\"9466233 \" target=\"_blank\">",
"        9466233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomsen PH, Ebbesen C, and Persson C, \"Long-Term Experience With Citalopram in the Treatment of Adolescent OCD,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2001, 40(8):895-902.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/11501688/pubmed\" id=\"11501688\" target=\"_blank\">",
"        11501688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Knorring AL, Olsson GI, Thomsen PH, et al, \"A Randomized, Double-Blind, Placebo-Controlled Study of Citalopram in Adolescents With Major Depressive Disorder,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2006, 26(3):311-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/16702897/pubmed\" id=\"16702897\" target=\"_blank\">",
"        16702897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, Robb AS, Findling RL, et al, &ldquo;A Randomized, Placebo-Controlled Trial of Citalopram for the Treatment of Major Depression in Children and Adolescents,&rdquo;",
"      <i>",
"       Am J Psych",
"      </i>",
"      , 2004, 161(6):1079-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/16/38152/abstract-text/15169696/pubmed\" id=\"15169696\" target=\"_blank\">",
"        15169696",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12972 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38152=[""].join("\n");
var outline_f37_16_38152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708670\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005975\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006010\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151959\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151943\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874419\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4417658\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005999\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005976\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152036\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152033\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005983\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4005931\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005984\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152019\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151952\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4417619\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151954\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151968\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006017\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006001\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4005932\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006003\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006021\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4417659\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12972|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=related_link\">",
"      Citalopram: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/49/12054?source=related_link\">",
"      Citalopram: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_16_38153="Sarcoptes scabiei";
var content_f37_16_38153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79567%7EDERM%2F65513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79567%7EDERM%2F65513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sarcoptes scabiei and eggs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies skin scraping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several oval eggs and multiple small, brown feces are present in this specimen. A mite is visible in the upper right corner of the image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38153=[""].join("\n");
var outline_f37_16_38153=null;
var title_f37_16_38154="Screening for cervical cancer: Rationale and recommendations";
var content_f37_16_38154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for cervical cancer: Rationale and recommendations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/16/38154/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38154/contributors\">",
"     Sarah Feldman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38154/contributors\">",
"     Brenda E Sirovich, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38154/contributors\">",
"     Anne Kathryn Goodman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/16/38154/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38154/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38154/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/16/38154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/16/38154/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/16/38154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pap smear has become a model for cancer screening. However, the effectiveness of Pap smear screening for cervical cancer has never been demonstrated in a randomized trial. Cervical cancer screening remains an evolving field with ongoing re-evaluation of Pap smear screening practices, the role of HPV testing, and development of new technologies.",
"   </p>",
"   <p>",
"    Cervical cancer screening can detect very early changes that, untreated, could lead to invasive cervical disease over the course of many years. The generally long latency between the detection of abnormalities by screening and the development of invasive cancer raises questions of the optimal frequency of testing and emphasizes the need to balance benefits of cervical cancer screening with potential harms, especially in younger women.",
"   </p>",
"   <p>",
"    This discussion will focus on specific recommendations for screening for cervical cancer. Issues to be addressed include appropriate ages for the initiation and discontinuation of screening; frequency of screening; and test options for screening. Management of cytologic abnormalities, techniques for performing and reporting cervical cancer screening, and screening women who are HIV positive are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"       \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"       \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=see_link\">",
"       \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link\">",
"       \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8248?source=see_link\">",
"       \"Cervical cancer screening tests: Evidence of effectiveness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=see_link\">",
"       \"Cervical cytology: Interpretation of results\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36934?source=see_link\">",
"       \"Screening for cervical cancer in HIV infected women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main types of cervical cancer: squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma of the cervix is more prevalent than adenocarcinoma. Both types are found in sexually active women. Infection with specific high-risk strains of human papillomavirus (HPV) is central to the pathogenesis of cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the approximately 30 to 40 HPV genotypes that infect the mucosa of the genital tract, eight (types 16, 18, 45, 31, 33, 52, 58, and 35) are responsible for 95 percent of cervical cancers, and two (types 16 and 18) are responsible for about 70 percent of cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/5\">",
"     5",
"    </a>",
"    ]. Two low-risk types (6 and 11) cause about 90 percent of benign anogenital warts. &nbsp;",
"   </p>",
"   <p>",
"    The risk of transmission of HPV correlates with the lifetime number of sex partners, but the prevalence of HPV infection is substantial (4 to 20 percent) even in those with one partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/6\">",
"     6",
"    </a>",
"    ]. In the United States (US), up to 50 percent of sexually active young women will have positive HPV tests within 36 months of first sexual activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and up to 57 percent of sexually active female adolescents are infected with HPV at any one point in time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most women will clear the HPV infection within 8 to 24 months; particularly in adolescents and young women, HPV infections and dysplasia are likely to resolve spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/10\">",
"     10",
"    </a>",
"    ]. Progression to cervical cancer requires persistent infection over many years. The HPV type and persistence of infection are the most important determinants of progression to squamous intraepithelial lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11\">",
"     11",
"    </a>",
"    ]. In a study in young women who underwent HPV testing at baseline and two years and were then followed for 12 years, the probability of developing cervical intraepithelial neoplasia grade 3 (CIN 3) was 47.4 percent for women in whom both tests were positive for HPV type 16 infection, compared to a risk of 2.3 percent for women who had two negative HPV tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/12\">",
"     12",
"    </a>",
"    ]. Cigarette smoking increases the risk of cervical cancer up to fourfold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/13\">",
"     13",
"    </a>",
"    ] and immunosuppression impairs the ability to clear the HPV infection and increases the risk of developing cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link&amp;anchor=H11#H11\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Cofactors in pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the US in 2013, there are estimated to be 12,340 new cases of invasive cervical cancer, and 4030 cancer-related deaths are expected; this represents approximately 1.5 percent of cancer deaths in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/15\">",
"     15",
"    </a>",
"    ]. Approximately half of cervical cancers diagnosed in the US between 2004 and 2006 were late stage, and correlated with lack of screening, particularly in older women and Hispanic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/16\">",
"     16",
"    </a>",
"    ]. Cervical cancer is the third most common cancer among women worldwide, with more than 85 percent of cases occurring in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The burden of cervical cancer extends beyond the impact of the disease itself, to the resources devoted to cervical cancer screening. Between 50 and 60 million Pap tests are performed in the US each year. Approximately 3.5 million of these are read as abnormal, and an estimated 2.5 million women undergo diagnostic colposcopy as a result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of HPV-related genital disease ranges from external genital warts or condyloma acuminata (affecting only 1 percent of infected women) to cytologic abnormalities representing active viral replication, to cervical dysplasia and malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical intraepithelial neoplasia (CIN) refers to preinvasive dysplasia of cervical epithelial cells, the precursor of malignant disease. CIN is categorized according to the depth of involvement and the atypicality of the cell as follows (",
"    <a class=\"graphic graphic_figure graphicRef60116 \" href=\"mobipreview.htm?4/20/4423\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CIN 1 &ndash; Considered a low-grade lesion, with mildly atypical cellular changes in the lower third of the epithelium.",
"     </li>",
"     <li>",
"      CIN 2 &ndash; Considered a high-grade lesion, with changes affecting the basal two-thirds of the epithelium. This is equivalent to moderate dysplasia.",
"     </li>",
"     <li>",
"      CIN 3 &ndash; Also a high-grade lesion, with cellular changes affecting more than two-thirds of the epithelium, including full thickness lesions. This was formerly called severe dysplasia or carcinoma in situ.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CIN 1 is not considered a cervical cancer precursor and is usually caused by low-risk HPV types. Unless persistent for more than two years, and diagnosed in women over age 21, treatment is not recommended. Rates of regression for low-grade lesions are as high as 75 percent at five years in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] and up to 91 percent at three years in adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/23\">",
"     23",
"    </a>",
"    ]. The high-grade dysplasia lesions, CIN 2 and CIN 3, are considered true precancers. Even so, up to 40 percent of CIN 2 may regress spontaneously, especially in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/21\">",
"     21",
"    </a>",
"    ]. The slow malignant transformation of these lesions leads to a long latency period for cervical carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical intraepithelial neoplasia is a pathologic diagnosis based upon evaluation of a tissue specimen obtained by biopsy, to be distinguished from squamous intraepithelial neoplasia, a cytologic diagnosis. While cytologic abnormalities are predictive of pathologic changes, there is not an absolute correspondence between cytology and pathology findings and histologic diagnosis is required for the diagnosis of cervical cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THE PAPANICOLAOU SMEAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pap test aims to identify abnormal cells sampled from the transformation zone, the junction of the ecto- and endocervix, where cervical dysplasia and cancers arise. Examples of normal and abnormal Pap smears are shown (",
"    <a class=\"graphic graphic_picture graphicRef55957 \" href=\"mobipreview.htm?32/59/33715\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52655 \" href=\"mobipreview.htm?35/7/35956\">",
"     picture 2",
"    </a>",
"    ). For conventional Pap smears, cervical samples obtained by brush and spatula are plated on a microscope slide and preserved with fixative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thin layer (or liquid-based) cytology, an alternative to conventional cytologic sampling, has been widely implemented in the US. Testing involves transferring samples from the brush and spatula into a liquid fixative solution; the cytology lab subsequently traps the loose cells onto a filter from which they are plated in a monolayer onto a glass slide. The collected specimen can also be used for other diagnostic assessments (ie, testing for gonorrhea, chlamydia, and HPV). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cytology report",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components of a cytology report include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A description of specimen type &mdash; conventional Pap smear or liquid-based cytology &nbsp;",
"     </li>",
"     <li>",
"      A description of specimen adequacy. Endocervical cells should be present to ensure adequate sampling",
"     </li>",
"     <li>",
"      A general categorization (optional) &mdash; negative, epithelial cell abnormality, or other",
"     </li>",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       interpretation/result",
"      </span>",
"      &mdash; either the specimen is negative for intraepithelial lesions and malignancy (although organisms or reactive changes may be present), or there is an epithelial cell abnormality as defined by the Bethesda 2001 classification, or there is another finding. This latter category may indicate some increased risk, as an example: endometrial cells in a woman over 40 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A description of any ancillary testing or automated review that was performed (eg, HPV, AutoPap)",
"     </li>",
"     <li>",
"      Educational notes and suggestions by the pathologist (optional)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details of this report are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=see_link\">",
"     \"Cervical cytology: Interpretation of results\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bethesda classification system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Papanicolaou test yields cytologic results, permitting examination of cells but not tissue structure. The diagnosis of cervical intraepithelial neoplasia or cervical carcinoma requires a tissue sample, obtained by biopsy of suspicious lesions, to make a histologic diagnosis.",
"   </p>",
"   <p>",
"    Pap smear results are now widely classified according to the Bethesda system, first introduced in 1988 and revised in 2001, to standardize and improve the clinical usefulness of Pap smear reports (",
"    <a class=\"graphic graphic_table graphicRef71416 \" href=\"mobipreview.htm?18/51/19261\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/24\">",
"     24",
"    </a>",
"    ]. The intent of the Bethesda system is to distinguish between abnormalities that are unlikely to progress to cancer and those that are more likely to indicate a precancerous or cancerous lesion. The Bethesda system also includes guidelines for determination of specimen accuracy. Cellular atypia is categorized in the Bethesda system as low-grade squamous intraepithelial lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=see_link\">",
"     \"Cervical cytology: Interpretation of results\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is clearly some correlation between abnormal cytologic results (eg, LSIL) and the histology subsequently demonstrated by biopsy (eg, CIN I), but direct correspondence occurs only in about half of patients. Particularly among young women, LSIL often regresses and represents a self-limited infection with HPV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to distinguish the atypical glandular cell (AGC) category from the more common atypical squamous cells (ASC). The presence of AGC or AIS (adenocarcinoma in situ) on cervical cytology is a significant marker for neoplasia of the endometrium, as well as of the cervix. A smear with AGC is associated with a premalignant or malignant lesion of the endocervix or endometrium in 10 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. All women (including adolescents) with atypical glandular cells or AIS should be referred for colposcopy with directed cervical biopsies and sampling of the endocervical canal; women over age 35 should also have an endometrial biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Test characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pap smear is intended as a screening test (to be administered to asymptomatic patients), rather than a diagnostic test (to confirm or refute the suspicion of disease). Reports of test sensitivity and specificity vary significantly, and the screening test is far from perfectly accurate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/31\">",
"     31",
"    </a>",
"    ]. Considerable interobserver variability in smear interpretation is seen, although variability decreases for smears with more severe abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sources of potential error in sampling and evaluating the Pap smear include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The clinician may not sample the area of cervical abnormality",
"     </li>",
"     <li>",
"      The abnormal cells may not be plated on the slide or transferred to the liquid medium",
"     </li>",
"     <li>",
"      The cells may not be adequately preserved with fixative",
"     </li>",
"     <li>",
"      The cytopathologist may not identify the abnormal cells",
"     </li>",
"     <li>",
"      The cytologist may inaccurately report the findings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Liquid-based cytology has several theoretical advantages over conventional cytology: less fixation and drying artifact, and less cellular obscuration on the slide resulting in fewer unsatisfactory tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/33\">",
"     33",
"    </a>",
"    ]. Systematic reviews of studies comparing conventional and liquid-based cytology, however, have not shown that liquid-based cytology detects significant cancer precursors more effectively than conventional cytology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The opportunity to retest the liquid preparation at a later date for HPV (ie, as a reflex test for women whose cytology results show equivocal or low-grade abnormalities) may prove advantageous in certain circumstances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, cases of invasive cervical cancer are more likely to represent failure to perform appropriate screening than inaccuracies of screening when performed. More than half of women who develop cervical cancer either have never had cervical cytology, have been screened sporadically, or have not been screened within the previous five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytologic screening for cervical cancer has never been evaluated in a randomized controlled trial. Evidence of its effectiveness in reducing the incidence of and mortality from cervical cancer comes exclusively from observational studies. Cervical cytology appears to be less sensitive for detecting endocervical glandular dysplasia and adenocarcinoma than for detecting squamous malignancy. Results of studies of the effectiveness of Pap smear screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8248?source=see_link\">",
"     \"Cervical cancer screening tests: Evidence of effectiveness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Follow-up of abnormal cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have abnormal cervical screening tests should have indicated follow-up, based upon findings of the screening test. Strategies for appropriate follow-up are discussed in separate topics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=see_link\">",
"     \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HPV TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of testing for high-risk HPV types is evolving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/35\">",
"     35",
"    </a>",
"    ]. It has been proposed both as a primary screening modality (either as an adjunct to, or instead of, cervical smear testing) and as a method to triage Pap smear results that are equivocal or show low-grade abnormalities.",
"   </p>",
"   <p>",
"    In the US, four types of HPV tests, listed below, are approved by the US Food and Drug Administration (FDA) for primary screening as a co-test with a Pap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/40\">",
"     40",
"    </a>",
"    ]. These tests will be referred to as &ldquo;HPV testing.&rdquo;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hybrid Capture 2 (the first test to receive FDA approval, in 2003) &mdash; Identifies the presence of any of 13 high-risk HPV types",
"     </li>",
"     <li>",
"      Cervista HPV HR test (approved in 2009) &mdash; Identifies the presence of any of 14 high-risk HPV types",
"     </li>",
"     <li>",
"      cobas HPV test &mdash; Detects HPV16 and 18 as well as a pooled result for an additional 12 high-risk subtypes",
"     </li>",
"     <li>",
"      Aptima mRNA test &mdash; Detects 14 high-risk subtypes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, Cervista has a test (Cervista",
"    <span class=\"nowrap\">",
"     16/18)",
"    </span>",
"    that detects only the HPV16 and HPV18 high-risk subtypes and is approved only for use in women 30 and over as a follow-up test after a positive HPV screen for the 14 high-risk types. The HPV",
"    <span class=\"nowrap\">",
"     16/18",
"    </span>",
"    test (hereafter referred to as \"HPV genotyping\") is intended to be used, adjunctively with cytology, as follow-up to a less-specific HPV test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary HPV screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV testing, either alone or in combination with cervical cytology, has been shown in multiple studies to be more sensitive than cervical cytology alone in detecting high- or low-grade cervical histopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/35,41-46\">",
"     35,41-46",
"    </a>",
"    ]. Poor specificity and correspondingly poor positive predictive value, however, limit the use of HPV testing alone as a primary screening modality, particularly in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details of studies that have compared HPV and cytologic screening are discussed separately. In brief summary, the following conclusions can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary HPV testing in women under 30 years of age results in substantial detection of transient HPV infections and unnecessary colposcopies.",
"     </li>",
"     <li>",
"      Adding HPV to routine primary Pap smear screening, or primary HPV testing alone in women over 30, appears to result in earlier diagnosis of high-grade lesions.",
"     </li>",
"     <li>",
"      One trial has demonstrated a decrease in the overall incidence of cancer with HPV testing, although a mortality benefit has not been demonstrated.",
"     </li>",
"     <li>",
"      Any strategy that includes HPV screening (with or without Pap smears, or with Pap smear as triage) increases the number of positive results from screening and the number of colposcopies performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8248?source=see_link\">",
"     \"Cervical cancer screening tests: Evidence of effectiveness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Use in areas with limited resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary HPV screening may be an effective screening modality in resource-poor areas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19160?source=see_link\">",
"     \"Screening for cervical cancer in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Follow-up of HPV testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening by HPV testing alone (without concurrent Pap testing) is not currently recommended in the United States, but may be a reasonable option for screening in geographic areas with limited cytology resources. Women 30 years and older who have been screened with an HPV test alone should have a Pap smear performed if the HPV test is positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/47\">",
"     47",
"    </a>",
"    ]; further evaluation should be based on the combined results of the HPV test and Pap smear. Women under age 30 are not recommended to undergo primary HPV testing.",
"   </p>",
"   <p>",
"    For women 30 years and older screened with a combination of Pap smear and HPV testing, a positive or negative HPV test can help inform the management of an abnormal Pap smear. A negative HPV test, in combination with a normal Pap smear, confers an extremely low risk of developing CIN 3 or greater within the next 10 years. Studies in Denmark and in the US have found this risk to be less than 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among women aged 30 and older with a positive HPV test in combination with a normal Pap smear, only a fraction will have undetected CIN 2 or greater at the time of screening, and most will clear their high-risk HPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, one study found that among those who failed to clear their high-risk HPV at one-year follow-up, over 10 percent had developed CIN 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8372719\">",
"    <span class=\"h3\">",
"     Normal Pap smear and positive HPV test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of a patient following HPV and Pap testing is shown in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef61527 \" href=\"mobipreview.htm?40/32/41473\">",
"     algorithm 1",
"    </a>",
"    ). Consensus guidelines recommend that women with a positive HPV test and negative cytology should have both tests repeated in 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11,54\">",
"     11,54",
"    </a>",
"    ]. If both tests at 12 months are negative, women can revert to routine screening. If the HPV test is persistently positive, they should undergo colposcopy. If the cytology is positive, they should have appropriate evaluation, regardless of HPV results. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Follow-up of abnormal cytology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440700697\">",
"    <span class=\"h3\">",
"     HPV genotyping",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to the above algorithm (repeating the HPV and Pap test at 12 months for an initial positive HPV and negative Pap) is based upon the differential risk conferred by HPV",
"    <span class=\"nowrap\">",
"     16/18,",
"    </span>",
"    compared with other high-risk HPV types (",
"    <a class=\"graphic graphic_algorithm graphicRef54413 \" href=\"mobipreview.htm?33/14/34021\">",
"     algorithm 2",
"    </a>",
"    ). Because women with a normal Pap smear who are positive for HPV",
"    <span class=\"nowrap\">",
"     16/18",
"    </span>",
"    have an 18 to 21 percent 10-year risk of developing CIN 3 (compared with a risk as low as 1.5 percent among those with",
"    <span class=\"nowrap\">",
"     non-16/18",
"    </span>",
"    high-risk types) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/50,55\">",
"     50,55",
"    </a>",
"    ], the HPV genotyping test may prove useful. It has been suggested that women over age 30 with a negative Pap smear and positive HPV test could undergo HPV genotyping. Women who are HPV",
"    <span class=\"nowrap\">",
"     16/18",
"    </span>",
"    positive would then be referred directly for colposcopy. Those with a negative HPV",
"    <span class=\"nowrap\">",
"     16/18",
"    </span>",
"    would return in 12 months for a Pap smear and HPV test. However, this strategy has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     HPV testing as triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reflex HPV testing for equivocal cytology test results (atypical squamous cells of undetermined significance, ASC-US) or those with low-grade abnormalities (low-grade squamous intraepithelial lesion, LSIL) has been evaluated as an alternative to conventional follow-up (immediate colposcopy or repeat cytology every six months) in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/41,56,57\">",
"     41,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The preferred approach for evaluation of women age 21 or older with ASC-US is reflex high-risk HPV testing with triage for colposcopy if the HPV test is positive. Healthy women under 21 should not be screened, and there is no role for reflex HPV testing in this age group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHER SCREENING MODALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Visual inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions identified by visual inspection warrant biopsy even in the presence of a normal cervical smear. Visual inspection with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    (VIA) or Lugol's iodine is used for cervical cancer screening in some developing countries with inadequate resources for population-based cytologic screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19160?source=see_link\">",
"     \"Screening for cervical cancer in resource-limited settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25156?source=see_link\">",
"     \"Cervical cancer screening tests: Visual inspection methods\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Computerized Pap screening or rescreening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computerized automated screening of Pap slides has been developed, but the role for this technology has not been definitively determined. Available technologies include Autopap, PapNet, and ThinPrep. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1146544\">",
"    <span class=\"h1\">",
"     RISKS OF SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal cervical cytology results are relatively common. It is estimated that between 50 and 60 million cervical cytology tests (Pap tests) are performed each year in the US. Approximately 3.5 million of these are read as abnormal, and an estimated 2.5 million women undergo diagnostic colposcopy as a result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A population-based study in Australia estimated that a 15-year-old woman faces a 77 percent lifetime risk of undergoing at least one colposcopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of screening fall into four categories: discomfort and inconvenience, psychosocial consequences, adverse health outcomes, and costs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The discomfort and inconvenience of Pap smear screening are apparent, although not easily measurable; both increase with the frequency and duration of screening, and may be particularly relevant for adolescents and older adults.",
"     </li>",
"     <li>",
"      A number of studies have examined the psychosocial consequences of screening. High levels of anxiety are associated with colposcopy referral for women with both high-grade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/59\">",
"       59",
"      </a>",
"      ] and low-grade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/60\">",
"       60",
"      </a>",
"      ] abnormalities, and with surveillance for mild smear abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/61\">",
"       61",
"      </a>",
"      ]. Anxiety is heightened in women with a positive HPV test [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/62\">",
"       62",
"      </a>",
"      ] and in younger women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/60,62\">",
"       60,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adverse health outcomes related to cervical cancer screening arise from the downstream consequences of diagnosing and treating abnormalities. Large scale studies on the long-term effects of loop electrosurgical excisional procedure (LEEP), laser ablation and conization on fertility and pregnancy are not available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/63\">",
"       63",
"      </a>",
"      ]; a 2006 meta-analysis of smaller studies found an association between cold knife conization and preterm delivery (RR 2.59, 95% CI 1.80-3.72) and low birthweight (RR 2.53, 1.19-5.46) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/64\">",
"       64",
"      </a>",
"      ]. Findings were similar for LEEP and showed a similar but nonsignificant trend for laser conization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"       \"Cervical intraepithelial neoplasia: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The costs of cervical cancer screening include both monetary and opportunity costs. Annual spending on cervical cancer screening is estimated to exceed $7.5 billion. Opportunity costs relate to overlooking potentially more important health care issues during medical visits in which Pap smear screening is discussed and performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SCREENING PARAMETERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Initial screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;While sexually active adolescents are more likely than adult women to become infected with HPV and to have abnormal cervical cytology screening, most of these abnormalities are transient and cervical cancer is exceedingly rare in young women. Based upon data from Surveillance Epidemiology and End Results (SEER) 2002-2006, the incidence of cervical cancer is 1 to 2 cases per million females aged 15 to 19 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/65\">",
"     65",
"    </a>",
"    ]. Furthermore, treatment for abnormal cytology has long-term effects. Thus, the benefits of adolescent screening may be offset by potential harms, weighing against aggressive screening in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cumulative risk over three years of an HPV-negative adolescent developing an HPV infection was nearly 50 percent in a study in the UK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/67\">",
"     67",
"    </a>",
"    ]; other estimates are in similar range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/10,68\">",
"     10,68",
"    </a>",
"    ]. Rates of ASC-US (10 to 12 percent) and LSIL (4 to 8 percent) are also consistently higher in adolescent women than in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. However, 90 to 95 percent of low-grade lesions in adolescent women, as well as many high-grade lesions, regress spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/23,71,72\">",
"     23,71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caution is required in developing a screening and treatment strategy for adolescents. The long-term consequences of interventions for follow-up of abnormal cytology tests, including laser ablation, LEEP (loop electrosurgical excision procedure), and conization, are unknown. Observational studies indicate an association between excisional cervical procedures and subsequent pregnancy outcomes, including preterm delivery and low birth weight neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most groups recommend delaying screening until age 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11,73,74\">",
"     11,73,74",
"    </a>",
"    ]. An exception would be for women with HIV infection or women with SLE or organ transplants who are receiving long-term immunosuppression. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Recommendations of professional organizations'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15399523\">",
"     'Immunocompromised women'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Reported sexual abstinence is not considered an exclusion in general screening recommendations. Women may have a variety of reasons for not disclosing prior sexual activity including social, religious, or cultural norms, as well as prior sexual abuse. In particular, women who have been sexually abused or raped are often reluctant to acknowledge this history and abuse may underlie the decision to not engage in subsequent sexual activity. After receiving appropriate counseling regarding the specific risks and benefits of screening, individual women may decide they do not wish to undergo either examination or testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Discontinuing screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little controversy that targeting never- and under-screened women is an appropriate screening strategy. Older women who have never been screened have the highest incidence of and mortality from cervical cancer and benefit the most from screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]. In the US, Medicare began providing reimbursement for Pap smear screening in 1990, motivated by findings that up to 40 percent of older adult women had never had a Pap smear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/79-82\">",
"     79-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, for older women who have undergone appropriate screening, there is little benefit of continuing to screen this population. The incidence of CIN and carcinoma in situ peaks in the mid-reproductive years and begins to decline in the fourth decade of life. Cervical cancer is no more aggressive in older women, and high-grade lesions are rare among older women who have been previously screened.",
"   </p>",
"   <p>",
"    Several studies illustrate the low yield and poor positive predictive value of screening among previously screened older women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 312,000 participants in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), a Federally funded program for low-income and uninsured women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/83\">",
"       83",
"      </a>",
"      ], those aged 65 and older had the lowest risk of an abnormal Pap smear (2.8 percent ASCUS; 1.0 percent a more severe abnormality) and the lowest risk of serious pathology (0.2 percent had CIN II or worse confirmed at biopsy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of an abnormality on a subsequent smear was even lower for the 130,000 women from the same program who had a normal Pap smear result at program entry and at least one additional smear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/85\">",
"       85",
"      </a>",
"      ]. Women aged 65 and older again had the lowest risk of any abnormality (2.2 percent ASCUS, 0.4 percent a more severe abnormality).",
"     </li>",
"     <li>",
"      Pap smear abnormalities among previously screened older women have poor positive predictive value for significant pathology. The incidence of new cytologic abnormalities within two years of a normal Pap smear was 2.3 percent per year among 2561 postmenopausal women (median age 67 years) participating in the Heart and",
"      <span class=\"nowrap\">",
"       Estrogen/progestin",
"      </span>",
"      Replacement Study (HERS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/86\">",
"       86",
"      </a>",
"      ]. Only one of the 110 abnormal Pap smears proved to have high-grade cervical histology (positive predictive value 0.9 percent). One additional woman had high-grade vaginal intraepithelial neoplasia.",
"     </li>",
"     <li>",
"      Cytology results were evaluated for 17,000 women aged 50 to 79 participating in the Women's Health Initiative who underwent Pap smear screening at baseline, three years, and six years (and more frequently if indicated) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/87\">",
"       87",
"      </a>",
"      ]. The risk of high-grade cytological abnormalities (HSIL or cancer) for women with a normal smear at baseline was low (7.1 per 10,000 person-years). Colposcopic data were not available for this study.",
"     </li>",
"     <li>",
"      The prevalence of &ldquo;atypical cervical cells, cannot exclude high-grade lesion (ASC-H)&rdquo; was compared for pre- and postmenopausal women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/88\">",
"       88",
"      </a>",
"      ]. High-grade histology was found in 6 percent of postmenopausal women, compared with 22 percent of pre-menopausal women. Thus, the diagnosis of ASC-H in postmenopausal women might reasonably require less aggressive surveillance and treatment than in younger women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No published studies directly evaluate the effectiveness of screening for older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/89\">",
"     89",
"    </a>",
"    ]. Although cervical cancer mortality increases after age 65, the benefit of screening declines with age, due to competing causes of death and lag time in the realization of screening benefits. Potential screening benefits need to be balanced against the potential harms of cervical cancer screening in older women. (See",
"    <a class=\"local\" href=\"#H1146544\">",
"     'Risks of screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Follow-up procedures are common among older women; among women over age 65 insured by Medicare in the US, 39 in 1000 require follow-up, with nine patients requiring colposcopy or more invasive procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/90\">",
"     90",
"    </a>",
"    ]. Pitfalls of screening in this population include patient refusal or failure to follow-up, false-positive tests leading to unnecessary procedures including hysterectomy, and mortality due to unrelated causes while undergoing evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/91-93\">",
"     91-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While ongoing screening for older women who have undergone regular screening may cause more harm than benefit, it is also clear that screening older women who have never been screened or who have been inadequately screened will detect treatable disease and improve outcomes. Modeling studies suggest that screening older women who have never been screened could reduce mortality by 74 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/94\">",
"     94",
"    </a>",
"    ]. One proposed strategy for such women would be to screen them every two to five years, ending at age 70 to 75 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, women who have a history of CIN 2, CIN 3, or adenocarcinoma in situ who have been appropriately managed (or in whom disease has spontaneously regressed) should be routinely screened for at least 20 years following diagnosis, even if this extends screening past age 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that women aged 65 and older with no increased risk and who have had adequate prior screening",
"    <strong>",
"     not",
"    </strong>",
"    undergo screening for cervical cancer.",
"   </p>",
"   <p>",
"    Outside the realm of screening, older women who have signs or symptoms of cervical disease (eg, abnormality on visualization or palpation of the cervix, postmenopausal bleeding, abnormal discharge, pelvic pain, or change in bowel or bladder function) should undergo appropriate diagnostic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Screening frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary determinants of screening frequency should be the duration of the preclinical treatable phase of the disease (up to 10 to 20 years for cervical cancer), and the sensitivity of the screening test (modest for cervical cytology) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/95\">",
"     95",
"    </a>",
"    ]. No screening test has perfect sensitivity, and preventing all cervical cancer is not realistic. Pap smear screening in the US was initially implemented as an annual test, with subsequent reconsideration of optimal screening frequency. In determining screening frequency, a balance needs to be determined between the risk of interval cancers and the risk of harms from screening. (See",
"    <a class=\"local\" href=\"#H1146544\">",
"     'Risks of screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The relative effectiveness of different cervical smear screening intervals in reducing the incidence and mortality of cervical cancer is based upon observational data and modeling studies, in the absence of randomized trials. The following modelling studies have compared predicted outcomes for different screening intervals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Agency for Research on Cancer (IARC) modeled the effectiveness of different screening intervals, using data from large screening programs in eight countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/96\">",
"       96",
"      </a>",
"      ]. Protection from cervical cancer remained high for at least three years after the last negative cervical cytology screen and was substantial up to 10 years. The estimated reduction in cumulative incidence of invasive cervical cancer among women aged 35 to 64 fell minimally when the screening interval was increased from one year (93.5 percent reduction) to two years (92.5 percent) to three years (90.8 percent).",
"     </li>",
"     <li>",
"      For women under age 30, a sensitivity analysis performed for the US Preventive Services Task Force predicted that twice as many colposcopies would be performed if screening were performed annually compared with screening every three years, with only a slightly greater reduction in cancer risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using a Markov model, it was predicted that after three or more negative cervical smears, annual compared to triennial Pap smear would detect three more cases of cervical cancer among 100,000 women aged 30 to 44 years; one more case among 100,000 women aged 45 to 59 years, and no excess cases in women 60 to 64 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/98\">",
"       98",
"      </a>",
"      ]. Women under age 30 showed the greatest benefit of annual screening (five fewer cases per 100,000).",
"     </li>",
"     <li>",
"      Modelling studies have also shown that screening with a combination of cervical smear cytology and HPV testing every five years (for women over age 30) is as effective as screening with cervical cytology alone every three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/94\">",
"       94",
"      </a>",
"      ]. Comparing co-testing every three years with co-testing every five years for women aged 40, the decrease in predicted lifetime cancer risk was marginal (0.39 percent versus 0.61 percent), while the longer screening interval was predicted to generate significantly fewer colposcopies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational studies have also addressed the relative benefits of different cervical smear screening intervals. These studies evaluated conventional, rather than liquid based, cervical cytology smears, and none included HPV testing. Representative findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rates of high-grade cytologic abnormalities (HSIL or worse) in the observational NBCCEDP study were similar, regardless of whether women had their next cervical smear one, two, or three years after their three consecutive normal cervical cytology tests (incidence 25, 29, and 33 per 10,000, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of serious cervical histology (CIN II or worse) within two years of a normal smear was negligible in the HERS study (1 case per 4895 person-years of follow-up) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/86\">",
"       86",
"      </a>",
"      ]. One hundred and ten women needed to undergo 231 additional interventions to detect the single case. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Discontinuing screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A matched case-control study of invasive squamous cell cervical cancer found that, compared with a one-year screening interval, the odds of cervical cancer increased for two-year (OR 1.72) and three-year (OR 2.06) screening intervals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/100\">",
"       100",
"      </a>",
"      ]. The authors cautioned that these results should be interpreted in the context of the low absolute risk of developing cervical cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, annual screening has been shown to double or triple the number of downstream interventions, including colposcopies, compared with triennial screening while only marginally increasing the detection of cervical cancer. A synthesis of several studies in women aged 21 to 29 years predicted that the lifetime risk of death due to cervical cancer would be 0.05, 0.05, and 0.03 per 1000 women for screening every three years, two years, and annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/73\">",
"     73",
"    </a>",
"    ]. Guideline-issuing organizations in the US recommend screening with cytology alone every three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11,73,74\">",
"     11,73,74",
"    </a>",
"    ]. For women over age 30, screening options include the combination of cytology and HPV testing (co-testing) at five year intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11,73,74\">",
"     11,73,74",
"    </a>",
"    ]. More frequent screening is indicated for women with risk factors (HIV infection, immunocompromise, in utero exposure to diethylstilbestrol [DES], or history of prior CIN 2, CIN 3, or cervical cancer). (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Frequency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     HPV vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Introduction of the HPV vaccine for female adolescents is anticipated to have a significant impact on their risk for cervical abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A cost-effectiveness model based on assumptions of vaccine effectiveness suggests that screening could be initiated later and performed less frequently in women who were vaccinated as preadolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/102\">",
"     102",
"    </a>",
"    ]. However, the optimal approach to cervical cancer screening in women who have received an HPV vaccine remains uncertain. The vaccine does not provide immunity against HPV types responsible for 30 percent of cervical cancers, and some vaccine recipients may have already been infected with high-risk HPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/5\">",
"     5",
"    </a>",
"    ]. Until data from clinical trials are available, standard screening recommendations should be observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/5,11,73,74,103\">",
"     5,11,73,74,103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prior hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have undergone a hysterectomy in which the cervix was removed (representing over 95 percent of hysterectomies currently performed in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/104\">",
"     104",
"    </a>",
"    ]) are at a vanishingly small risk of cervical cancer. Although it was once believed that women without a uterus were at increased risk for vaginal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/105-109\">",
"     105-109",
"    </a>",
"    ], studies show no association between total hysterectomy for benign disease and subsequent vaginal carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/109-114\">",
"     109-114",
"    </a>",
"    ]. In one study of over 10,000 vaginal cuff smears obtained from 6265 women, 1 percent of cervical cytology smears were abnormal, and the positive predictive value of the smear for predicting vaginal cancer was 0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/111\">",
"     111",
"    </a>",
"    ]. There has never been a randomized controlled trial of screening in women with hysterectomy.",
"   </p>",
"   <p>",
"    Certain groups of women may warrant continued screening after hysterectomy, although there are limited studies of cervical cytology screening in these groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link&amp;anchor=H31#H31\">",
"     \"Cervical intraepithelial neoplasia: Management\", section on 'Post-hysterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who have undergone subtotal hysterectomy, leaving the cervix intact, likely share the same risk of cervical cancer as women with an intact uterus and cervix. Such women represent a small minority of women who have undergone hysterectomy. For women who are uncertain if their cervix was removed at the time of hysterectomy, a pelvic exam is essential to determine the ongoing need for cervical cancer screening.",
"     </li>",
"     <li>",
"      Women who have undergone hysterectomy because of cervical cancer typically undergo cervical cytology tests for surveillance for local recurrence at the anastomotic site. Prospective studies of this practice are unavailable and retrospective studies, which all lack control groups, show variable yields on cytology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/115-118\">",
"       115-118",
"      </a>",
"      ]. ACOG recommends annual screening for at least 20 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7976?source=see_link&amp;anchor=H23#H23\">",
"       \"Management of locally advanced cervical cancer\", section on 'Posttreatment surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women who have had a hysterectomy and who have history of CIN 2 or CIN 3, it is reasonable to recommend continuing surveillance for recurrent CIN, although rates of vaginal intraepithelial neoplasia following hysterectomy for CIN are low (0.9 to 6.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/119\">",
"       119",
"      </a>",
"      ], and the risk of vaginal cancer almost nil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/120\">",
"       120",
"      </a>",
"      ]. Evidence in support of a specific duration of further screening after hysterectomy is scant. ACOG recommends ongoing screening for at least 20 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11\">",
"       11",
"      </a>",
"      ], citing a review indicating ongoing risk for invasive neoplasia in women who have been treated for CIN (although these data largely reflect women who did not undergo hysterectomy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/121\">",
"       121",
"      </a>",
"      ]. We believe that women who have undergone total hysterectomy for CIN 2 or CIN 3 can safely discontinue screening after 10 to 20 years, including at least three consecutive negative screening tests.",
"     </li>",
"     <li>",
"      Women exposed in utero to diethylstilbestrol (DES) who are at somewhat increased risk of gynecologic malignancies, particularly clear cell adenocarcinoma of the vagina, may warrant continued screening. (See",
"      <a class=\"local\" href=\"#H16975503\">",
"       'Diethylstilbestrol (DES) exposed women'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The role of screening in women with HIV infection who have had a hysterectomy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36934?source=see_link\">",
"       \"Screening for cervical cancer in HIV infected women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these findings, we recommend that women who have undergone total hysterectomy (including removal of the cervix) for indications unrelated to cervical cancer or cancer precursors",
"    <strong>",
"     not",
"    </strong>",
"    undergo screening for cervical cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16975495\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16975503\">",
"    <span class=\"h3\">",
"     Diethylstilbestrol (DES) exposed women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women exposed in utero to diethylstilbestrol (DES) who are at elevated (although low) risk of gynecologic malignancies, particularly clear cell adenocarcinoma of the vagina, may warrant continued screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/73,122\">",
"     73,122",
"    </a>",
"    ]. However, it should be noted that the average age of vaginal cancer in DES-exposed women is 19, and there are virtually no reported cases over age 35. The association between DES exposure and vaginal cancer was reported in 1971, and the youngest women (in the United States) are likely to be over 40 years of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=see_link\">",
"     \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who themselves took DES during pregnancy, while at increased risk for breast cancer, have no increased risk for cervical, vaginal, or other cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/123\">",
"     123",
"    </a>",
"    ]. Such women should be screened for cervical cancer in the same manner as the average-risk general population. Although evidence is not available regarding the need for ongoing Pap surveillance in older women who had in utero DES exposure, guidelines from the National Cancer Institute recommend that daughters of women who took DES in pregnancy have annual pelvic examination and screening for vaginal and cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/124\">",
"     124",
"    </a>",
"    ]. Screening should involve Pap testing rather than HPV tests in these women. There are no studies evaluating when pap smear screening can be discontinued, although there is a theoretical concern that there may be a second peak in related cancers as the cohort ages. Until further data are available, we currently are continuing with surveillance screening. Some have suggested that the screening interval may be lengthened to three years after age 70. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=see_link&amp;anchor=H19311264#H19311264\">",
"     \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\", section on 'DES daughters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15399523\">",
"    <span class=\"h3\">",
"     Immunocompromised women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are infected with HIV are at increased risk for the development of cervical cancer, and have increased rates of high-grade cervical dysplasia, and HPV persistence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/125-127\">",
"     125-127",
"    </a>",
"    ]. For this reason, guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the Centers for Disease Control recommend earlier onset of screening and more intensive screening for HIV-positive women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36934?source=see_link\">",
"     \"Screening for cervical cancer in HIV infected women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36934?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for cervical cancer in HIV infected women\", section on 'Cervical cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other immunosuppressed women are also at increased risk for cervical cancer, with the most data available for patients with systemic lupus erythematosus (SLE) and women undergoing organ transplants. Rates of abnormal Pap tests, high-grade dysplasia and persistence of high-risk HPV subtypes are significantly higher in women with SLE who are receiving immunosuppressive therapy than in patients on immunosuppressive treatment for other conditions or in those with milder forms of lupus who are not on treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/14,128-131\">",
"     14,128-131",
"    </a>",
"    ]. Data are not available to distinguish cancer rates in younger versus older patients in the HIV, SLE, or transplant groups. Given the decreased rates of clearance of HPV infection and the increased rates of dysplasia and cancer in these groups, however, ACOG has recommended initiating screening in these immunosuppressed patients with the onset of sexual activity and not waiting until age 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/66\">",
"     66",
"    </a>",
"    ]. Recommendations also advise that screening be undertaken twice in the first year and then annually for women with HIV, organ transplant, or long-term immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF PROFESSIONAL ORGANIZATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H286231691\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer screening guidelines in the US are issued by several organizations: the U.S. Preventive Services Task Force (USPSTF) in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/74\">",
"     74",
"    </a>",
"    ]; the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology",
"    <span class=\"nowrap\">",
"     (ACS/ASCCP/ASCP)",
"    </span>",
"    in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/73\">",
"     73",
"    </a>",
"    ]; and the American College of Obstetricians and Gynecologists (ACOG) in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11\">",
"     11",
"    </a>",
"    ]. Guidelines issued by these groups are specific with respect to starting age, stopping age, screening frequency, and groups for whom the standard recommendations do not apply (",
"    <a class=\"graphic graphic_table graphicRef82951 \" href=\"mobipreview.htm?24/21/24925\">",
"     table 2",
"    </a>",
"    ). The National Comprehensive Cancer Network (NCCN) also published guidelines in 2010 that, essentially, are consistent with the 2009 guidelines from ACOG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All US guidelines strongly recommend screening for cervical cancer, with minor differences in the recommended parameters of screening. A US survey of clinician's responses to screening vignettes, however, indicated that fewer than 25 percent would recommend screening consistent with the care advised by the guidelines current at the time of the survey; choices representing overuse were most frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Starting age",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women at average risk of cervical cancer, the US guidelines recommend screening be initiated at age 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11,73,74\">",
"     11,73,74",
"    </a>",
"    ]. ACOG recommends initiating screening at the time of initial intercourse for women under 21 who have HIV infection or who are on chronic immunosuppressive therapy for systemic lupus erythematosus or post organ transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Stopping age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The USPSTF and",
"    <span class=\"nowrap\">",
"     ACS/ASCCP/ASCP",
"    </span>",
"    and ACOG guidelines suggest stopping screening at age 65 for women who have had adequate recent screening. Adequate screening is defined as three consecutive negative cytology tests or two consecutive negative",
"    <span class=\"nowrap\">",
"     HPV/Pap",
"    </span>",
"    co-tests in the 10 years prior to stopping, with the most recent test within five years. Women should continue testing for 20 years after management of a high-grade precancerous lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51076976\">",
"    <span class=\"h3\">",
"     Screening modality",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All major guidelines acknowledge that there is no difference between liquid-based and conventional smear cytology.",
"     </li>",
"     <li>",
"      None of the US guidelines advise primary screening with HPV testing alone, although they recognize that this might increase screening uptake in underserved populations and that more data are needed.",
"     </li>",
"     <li>",
"      All guidelines recommend only cytology screening for women aged 21 to 29 years.",
"     </li>",
"     <li>",
"      Recommendations differ regarding the combination of cytology plus HPV testing (co-testing) for women 30 years and older. The",
"      <span class=\"nowrap\">",
"       ACS/ASCCP/ASCP",
"      </span>",
"      and ACOG guidelines prefer screening with combination cytology and HPV testing every five years for this age group, and USPSTF suggests offering co-testing every five years to women who wish to increase the interval of screening with recognition that this may lead to additional testing, but suggest screening with cervical cytology every three years for women 21 to 65 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of testing is dependent upon the screening test used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For cytology, which is the only option for women aged 21 through 29 years, USPSTF,",
"      <span class=\"nowrap\">",
"       ACS/ASCCP/ASCP,",
"      </span>",
"      and ACOG guidelines recommend testing every three years. For co-testing with cytology and HPV tests for women over 30 years of age, the USPSTF,",
"      <span class=\"nowrap\">",
"       ACS/ASCCP/ASCP,",
"      </span>",
"      and ACOG recommend five years intervals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ACS specifies certain risk groups that may require more frequent screening: HIV infection, immunosuppression, or in utero DES exposure. ACOG recommends annual screening for women who have been treated in the past for CIN 2, CIN 3, or cervical cancer. ACOG recommends screening twice in the first year for women who are immunocompromised and annually thereafter. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Women who have undergone hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All three organizations concur that women who have undergone total hysterectomy for benign disease should discontinue screening for cervical cancer. The ACS recommends screening until three annual tests are negative for women who have had CIN 2 or 3, unless three negative tests were documented prior to their hysterectomy and recommends ongoing screening for DES-exposed women. ACOG advises ongoing screening for CIN 2 or CIN 3 for 20 years after treatment, including women who will be older than 65 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     International perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most industrialized Western nations, Pap smear tests are performed as part of large scale national or provincial centrally organized programs. Most countries have designated national screening policies with marked variation between countries.",
"   </p>",
"   <p>",
"    A table summarizes the national screening policies of over a dozen industrialized nations (",
"    <a class=\"graphic graphic_table graphicRef72903 \" href=\"mobipreview.htm?11/32/11790\">",
"     table 3",
"    </a>",
"    ). Starting age for Pap smears ranges from age 18 (in Australia) to 30 (in the Netherlands and Finland). Stopping age ranges from 58 (in Sweden) to 70 (in Australia and Canada), or indefinite (in Germany). Screening frequency ranges from annual (Germany) to every five years (the Netherlands, Finland, and the United Kingdom). These policies result in a recommended (minimum) number of lifetime smears between 7 and 50 or more.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     ADEQUACY OF SCREENING AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The more commonly discussed aspects of cervical cancer screening (type of testing, frequency and age to initiate and discontinue) have less impact on overall screening effectiveness than whether women receive any screening or have appropriate follow-up for abnormal tests. Half of women with newly diagnosed invasive cervical carcinoma have never had a Pap smear; another 10 percent have not had a smear in the past five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Actively inviting women to schedule an appointment for cervical cancer screening appears to be the most effective way to obtain participation in a screening program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/134\">",
"     134",
"    </a>",
"    ], though even active solicitation resulted in less than a 20 percent increase in screening in one systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/135\">",
"     135",
"    </a>",
"    ]. The most effective single intervention used a dedicated nurse practitioner, and offered same-day screening (33 percent increase in screening).",
"   </p>",
"   <p>",
"    In a survey of screening in the United States in 2010, 86.7 percent of women aged 21 to 65 years with a cervix reported having had a Pap test within the preceding three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/136\">",
"     136",
"    </a>",
"    ]. Never-screened and under-screened women tend to be those with no usual source of health care, the uninsured, and women who immigrated to the US within the past 10 years. Urgent care clinic visits can be used as an opportunity to obtain a cervical cytology test in women who are unlikely to otherwise comply with cervical cancer screening recommendations; such an approach dramatically increases the number of women screened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/137\">",
"     137",
"    </a>",
"    ]. However, patient follow-up in this setting can be more difficult than in the longitudinal care setting.",
"   </p>",
"   <p>",
"    The effectiveness of Pap test screening hinges on adequate follow-up and treatment for abnormal cytologic results. Patients with abnormal cervical cytology require further evaluation, which may include HPV testing, colposcopy, cervical biopsy, endometrial sampling, or a diagnostic excisional procedure, depending upon the severity and nature of the cytologic results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=see_link\">",
"     \"Cervical cytology: Interpretation of results\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inadequate follow-up of abnormal Pap smears performed months or years prior to the diagnosis of cancer was found in up to 13 percent of women with invasive cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/38,138-140\">",
"     38,138-140",
"    </a>",
"    ]. The median time from the date of the \"failed\" abnormal Pap smear to the cancer diagnosis was 22 months in one study; older age and poverty were associated with greater likelihood of a failed follow-up process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/141\">",
"     141",
"    </a>",
"    ]. Initiating a reminder system is helpful for ensuring compliance with follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/142,143\">",
"     142,143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite demonstrated health benefits from Pap testing, some women remain unwilling to undergo screening, and furthermore may be reluctant to pursue other health care because of their concerns regarding the pelvic exam. Women who decline Pap smear screening after having been informed in a clear and culturally sensitive manner of the expected benefits (and risks) of such screening, should be made to feel welcome to receive ongoing health care without risk of blame or discrimination as a result of their decision.",
"   </p>",
"   <p>",
"    A systematic review of 38 randomized trials of interventions to promote screening for cervical cancer found good evidence that invitation letters can increase cancer screening uptake, and more limited evidence that educational interventions are also effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/16/38154/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/8/15491?source=see_link\">",
"       \"Patient information: Pap tests (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/53/8019?source=see_link\">",
"       \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/57/14227?source=see_link\">",
"       \"Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2515?source=see_link\">",
"       \"Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/44/17092?source=see_link\">",
"       \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carcinoma of the cervix is a disease of sexually active women and is related to infection with specific high-risk strains of human papillomavirus (HPV). Risk factors include earlier onset of sexual activity, multiple partners, cigarette smoking, and immunosuppression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical cancer screening has the potential to detect precancerous lesions and prevent cancer, as well as to detect early-stage disease and decrease cancer mortality. We recommend that women aged 21 to 65 years who have a cervix receive screening for cervical cancer (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'The Papanicolaou smear'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Except where resources are limited, Pap smears (with or without HPV co-testing) are used for cervical cancer screening. Liquid-based testing has not significantly improved Pap test accuracy compared to conventional Pap screening. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'The Papanicolaou smear'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests are available to identify high-risk HPV types in cervical specimens, and HPV testing has been proposed for both primary screening and for triaging abnormal Pap smears. HPV testing performed concurrently with Pap smear screening (co-testing) may detect earlier cervical abnormalities than Pap smear alone, although it also leads to an increased rate of follow-up testing (colposcopy). We recommend that women under age 30",
"      <strong>",
"       not",
"      </strong>",
"      be screened with HPV testing (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The combination of HPV and Pap testing is an option for screening women age 30 and older. We suggest that HPV testing, without concurrent Pap smear, be used only for screening in areas with limited cytology resources (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). HPV testing is also used to triage equivocally abnormal Pap test results. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'HPV testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"       \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While high-quality evidence is not available to define the appropriate age to initiate testing, we suggest that screening for cervical cancer in most women be initiated no earlier than age 21, regardless of the age of initiation of sexual activity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Initial screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest Pap smear screening at intervals of every three years for average-risk women aged 21 through 29 years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For average-risk women aged 30 to 65 years, we suggest either Pap smear screening every three years or a combination of Pap smear and HPV testing every five years, if both initial tests are negative (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Women with increased risk for cervical cancer (eg, a history of DES exposure, CIN 2, CIN 3, or cervical cancer, HIV infection, or otherwise immunosuppressed) should have more frequent screening. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Screening frequency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that women aged 65 and older who have had adequate negative prior screening (three consecutive negative cytology tests or two consecutive negative co-tests within the previous 10 years, with the most recent test within the previous five years)",
"      <strong>",
"       not",
"      </strong>",
"      undergo screening for cervical cancer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Older women who have not been adequately screened should be screened (by either cytology every two to three years or co-testing every five years) until age 70 or 75 years. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Discontinuing screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that women who have undergone total hysterectomy (including removal of the cervix) for indications unrelated to cervical cancer or cervical cancer precursors",
"      <strong>",
"       not",
"      </strong>",
"      undergo screening for cervical cancer (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Prior hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cervical cancer occurs in women who have never been screened or who have had only sporadic screening. The effectiveness of Pap smear screening also hinges on adequate follow-up and treatment for abnormal results. Strategies for appropriate follow-up are discussed in separate topics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"       \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"       \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=see_link\">",
"       \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=see_link\">",
"       \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"       \"Cervical intraepithelial neoplasia: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rigorous systems for tracking and follow-up of Pap smear screening and results should be implemented. Opportunistic screening in settings outside of scheduled examinations (eg, emergency departments) should be considered for women who are unable to recall an up-to-date Pap smear, particularly for women without a usual source of care, without health insurance, and for recent immigrants. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Adequacy of screening and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/1\">",
"      Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/2\">",
"      Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/3\">",
"      Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/4\">",
"      Wallin KL, Wiklund F, Angstr&ouml;m T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999; 341:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/5\">",
"      Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 2009; 361:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/6\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005; 105:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/7\">",
"      Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285:2995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/8\">",
"      Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/9\">",
"      Moscicki AB, Ellenberg JH, Vermund SH, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000; 154:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/10\">",
"      Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/11\">",
"      Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol 2012; 120:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/12\">",
"      Kj&aelig;r SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/13\">",
"      Winkelstein W Jr. Smoking and cervical cancer--current status: a review. Am J Epidemiol 1990; 131:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/14\">",
"      Klumb EM, Ara&uacute;jo ML Jr, Jesus GR, et al. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol 2010; 16:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/15\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/16\">",
"      Henley SJ, King JB, German RR, et al. Surveillance of screening-detected cancers (colon and rectum, breast, and cervix) - United States, 2004-2006. MMWR Surveill Summ 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/17\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/18\">",
"      Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 2005; 10:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/19\">",
"      Kurman RJ, Henson DE, Herbst AL, et al. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994; 271:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/20\">",
"      Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/21\">",
"      Ost&ouml;r AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/22\">",
"      Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 92:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/23\">",
"      Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/24\">",
"      Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/25\">",
"      Sharpless KE, Schnatz PF, Mandavilli S, et al. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol 2005; 105:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/26\">",
"      Geier CS, Wilson M, Creasman W. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol 2001; 184:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/27\">",
"      Chhieng DC, Elgert P, Cohen JM, Cangiarella JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer 2001; 93:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/28\">",
"      DeSimone CP, Day ME, Tovar MM, et al. Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol 2006; 107:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/29\">",
"      Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006; 107:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/30\">",
"      Cox JT. ASCCP Practice Guidelines: Management of glandular abnormalities in the cervical smear. J Lower Gen Tract Dis 1997; 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/31\">",
"      Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/32\">",
"      Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/33\">",
"      Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007; 335:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/34\">",
"      Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/35\">",
"      Whitlock EP, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/36\">",
"      Hildesheim A, Hadjimichael O, Schwartz PE, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 1999; 180:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/37\">",
"      Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health 1995; 85:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/38\">",
"      Coleman DV, Poznansky JJ. Review of cervical smears from 76 women with invasive cervical cancer: cytological findings and medicolegal implications. Cytopathology 2006; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/39\">",
"      Abed Z, O'Leary M, Hand K, et al. Cervical screening history in patients with early stage carcinoma of the cervix. Ir Med J 2006; 99:140.",
"     </a>",
"    </li>",
"    <li>",
"     American Society for Colposcopy and Cervical Pathology. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. 2009 addendum. Available at: www.guideline.gov/summary/summary.aspx?doc_id=14698&amp;nbr=007268&amp;string=HPV (Accessed on August 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/41\">",
"      ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/42\">",
"      Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/43\">",
"      Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005; 97:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/44\">",
"      Denny LA, Wright TC Jr. Human papillomavirus testing and screening. Best Pract Res Clin Obstet Gynaecol 2005; 19:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/45\">",
"      Koliopoulos G, Arbyn M, Martin-Hirsch P, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/46\">",
"      Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/47\">",
"      Cox T, Cuzick J. HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecol Oncol 2006; 103:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/48\">",
"      Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004; 103:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/49\">",
"      Kjaer S, H&oslash;gdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006; 66:10630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/50\">",
"      Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/51\">",
"      Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/52\">",
"      Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/53\">",
"      Naucler P, Ryd W, T&ouml;rnberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/54\">",
"      Solomon D, Papillo JL, Davey DD, Cytopathology Education and Technology Consortium (CETC). Statement on human papillomavirus DNA test utilization. Cancer 2009; 117:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/55\">",
"      Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/56\">",
"      ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/57\">",
"      Cotton S, Sharp L, Little J, et al. The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial. BJOG 2010; 117:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/58\">",
"      Kavanagh AM, Santow G, Mitchell H. Consequences of current patterns of Pap smear and colposcopy use. J Med Screen 1996; 3:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/59\">",
"      Bell S, Porter M, Kitchener H, et al. Psychological response to cervical screening. Prev Med 1995; 24:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/60\">",
"      Gray NM, Sharp L, Cotton SC, et al. Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors. Br J Cancer 2006; 94:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/61\">",
"      Peters T, Somerset M, Baxter K, Wilkinson C. Anxiety among women with mild dyskaryosis: a randomized trial of an educational intervention. Br J Gen Pract 1999; 49:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/62\">",
"      Maissi E, Marteau TM, Hankins M, et al. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ 2004; 328:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/63\">",
"      Sawaya GF, Brown AD, Washington AE, Garber AM. Clinical practice. Current approaches to cervical-cancer screening. N Engl J Med 2001; 344:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/64\">",
"      Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367:489.",
"     </a>",
"    </li>",
"    <li>",
"     SEER cancer statistics review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009. Available at: file://seer.cancer.gov/csr/1975_2006 (Accessed on December 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/66\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 463: Cervical cancer in adolescents: screening, evaluation, and management. Obstet Gynecol 2010; 116:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/67\">",
"      Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/68\">",
"      Kahn JA, Hillard PJ, American Cancer Society, et al. Cervical cytology screening and management of abnormal cytology in adolescent girls. J Pediatr Adolesc Gynecol 2003; 16:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/69\">",
"      Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics 1999; 103:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/70\">",
"      Edelman M, Fox AS, Alderman EM, et al. Cervical Papanicolaou smear abnormalities in inner city Bronx adolescents: prevalence, progression, and immune modifiers. Cancer 1999; 87:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/71\">",
"      Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/72\">",
"      Szarewski A, Sasieni P. Cervical screening in adolescents--at least do no harm. Lancet 2004; 364:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/73\">",
"      Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/74\">",
"      Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/75\">",
"      Fletcher A. Screening for cancer of the cervix in elderly women. Lancet 1990; 335:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/76\">",
"      Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modelling study. BMJ 1999; 318:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/77\">",
"      Fahs MC, Mandelblatt J, Schechter C, Muller C. Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 1992; 117:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/78\">",
"      Power EJ. Pap smears, elderly women, and Medicare. Cancer Invest 1993; 11:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/79\">",
"      Celentano DD, Shapiro S, Weisman CS. Cancer preventive screening behavior among elderly women. Prev Med 1982; 11:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/80\">",
"      Mandelblatt J, Schechter C, Fahs M, Muller C. Clinical implications of screening for cervical cancer under Medicare. The natural history of cervical cancer in the elderly: what do we know? What do we need to know? Am J Obstet Gynecol 1991; 164:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/81\">",
"      Weinrich S, Coker AL, Weinrich M, et al. Predictors of Pap smear screening in socioeconomically disadvantaged elderly women. J Am Geriatr Soc 1995; 43:267.",
"     </a>",
"    </li>",
"    <li>",
"     Gluck ME, Wagner JL, Duffy BM. The use of preventive services by the elderly. Preventive Health Services under Medicare series, Paper 2. Office of Technology Assessment; Washington, DC 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/83\">",
"      Lawson HW, Henson R, Bobo JK, Kaeser MK. Implementing recommendations for the early detection of breast and cervical cancer among low-income women. MMWR Recomm Rep 2000; 49:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/84\">",
"      Lawson HW, Lee NC, Thames SF, et al. Cervical cancer screening among low-income women: results of a national screening program, 1991-1995. Obstet Gynecol 1998; 92:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/85\">",
"      Sawaya GF, Kerlikowske K, Lee NC, et al. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol 2000; 96:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/86\">",
"      Sawaya GF, Grady D, Kerlikowske K, et al. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). Ann Intern Med 2000; 133:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/87\">",
"      Yasmeen S, Romano PS, Pettinger M, et al. Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial. Obstet Gynecol 2006; 108:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/88\">",
"      Saad RS, Dabbs DJ, Kordunsky L, et al. Clinical significance of cytologic diagnosis of atypical squamous cells, cannot exclude high grade, in perimenopausal and postmenopausal women. Am J Clin Pathol 2006; 126:381.",
"     </a>",
"    </li>",
"    <li>",
"     IARC Working Group on Cervical Cancer Screening. Summary Chapter. In: Screening for cancer of the uterine cervix, IARC Scientific Publications No. 76, Hakama M, Miller AB, Day NE (Eds), IARC, Lyon 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/90\">",
"      Sirovich BE, Gottlieb DJ, Fisher ES. The burden of prevention: downstream consequences of Pap smear testing in the elderly. J Med Screen 2003; 10:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/91\">",
"      Mandelblatt J, Gopaul I, Wistreich M. Gynecological care of elderly women. Another look at Papanicolaou smear testing. JAMA 1986; 256:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/92\">",
"      Mandelblatt J, Traxler M, Lakin P, et al. Breast and cervical cancer screening of poor, elderly, black women: clinical results and implications. Harlem Study Team. Am J Prev Med 1993; 9:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/93\">",
"      Weintraub NT, Violi E, Freedman ML. Cervical cancer screening in women aged 65 and over. J Am Geriatr Soc 1987; 35:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/94\">",
"      Vesco KK, Whitlock EP, Eder M, et al. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/95\">",
"      Frame PS, Frame JS. Determinants of cancer screening frequency: the example of screening for cervical cancer. J Am Board Fam Pract 1998; 11:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/96\">",
"      Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. Br Med J (Clin Res Ed) 1986; 293:659.",
"     </a>",
"    </li>",
"    <li>",
"     Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cerivcal Cancer: A decision analysis for the U.S. Preventeive SErvices Task Force. file://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerdecan.pdf (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/98\">",
"      Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003; 349:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/99\">",
"      Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med 2008; 168:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/100\">",
"      Miller MG, Sung HY, Sawaya GF, et al. Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol 2003; 101:29.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA News. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by Human Papillomavirus. Released June 8, 2006. Available at: www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html (Accessed on September 20, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/102\">",
"      Goldhaber-Fiebert JD, Stout NK, Salomon JA, et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008; 100:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/103\">",
"      Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/104\">",
"      Sirovich BE, Welch HG. Cervical cancer screening among women without a cervix. JAMA 2004; 291:2990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/105\">",
"      Bell J, Sevin BU, Averette H, Nadji M. Vaginal cancer after hysterectomy for benign disease: value of cytologic screening. Obstet Gynecol 1984; 64:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/106\">",
"      McIntosh DG. Pap smear screening after hysterectomy. Compr Ther 1998; 24:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/107\">",
"      Ferris DG, Messing MJ, Crosby JH. Vaginal intraepithelial neoplasia III detected after hysterectomy for benign conditions. J Fam Pract 1995; 40:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/108\">",
"      D&aacute;vila RM, Miranda MC. Vaginal intraepithelial neoplasia and the Pap smear. Acta Cytol 2000; 44:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/109\">",
"      Fetters MD, Fischer G, Reed BD. Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease. JAMA 1996; 275:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/110\">",
"      Piscitelli JT, Bastian LA, Wilkes A, Simel DL. Cytologic screening after hysterectomy for benign disease. Am J Obstet Gynecol 1995; 173:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/111\">",
"      Pearce KF, Haefner HK, Sarwar SF, Nolan TE. Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. N Engl J Med 1996; 335:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/112\">",
"      Fox J, Remington P, Layde P, Klein G. The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. Am J Obstet Gynecol 1999; 180:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/113\">",
"      Videlefsky A, Grossl N, Denniston M, et al. Routine vaginal cuff smear testing in post-hysterectomy patients with benign uterine conditions: when is it indicated? J Am Board Fam Pract 2000; 13:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/114\">",
"      Farghaly H, Bourgeois D, Houser PM, et al. Routine vaginal Pap test is not useful in women status-post hysterectomy for benign disease. Diagn Cytopathol 2006; 34:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/115\">",
"      Gemmell J, Holmes DM, Duncan ID. How frequently need vaginal smears be taken after hysterectomy for cervical intraepithelial neoplasia? Br J Obstet Gynaecol 1990; 97:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/116\">",
"      Kalogirou D, Antoniou G, Karakitsos P, et al. Vaginal intraepithelial neoplasia (VAIN) following hysterectomy in patients treated for carcinoma in situ of the cervix. Eur J Gynaecol Oncol 1997; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/117\">",
"      Coughlan C, McAuliffe F, Bermingham N, Gleeson N. Vaginal cytology following primary hysterectomy for cervical cancer: is it useful? Ir J Med Sci 2006; 175:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/118\">",
"      Cooper AL, Dornfeld-Finke JM, Banks HW, et al. Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer? Obstet Gynecol 2006; 107:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/119\">",
"      Schockaert S, Poppe W, Arbyn M, et al. Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. Am J Obstet Gynecol 2008; 199:113.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/120\">",
"      Stokes-Lampard H, Wilson S, Waddell C, et al. Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. BJOG 2006; 113:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/121\">",
"      Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006; 118:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/122\">",
"      Anderson B, Watring WG, Edinger DD Jr, et al. Development of DES-associated clear-cell carcinoma: the importance of regular screening. Obstet Gynecol 1979; 53:293.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute. Clinician information: Identification and management of persons exposed to DES (Diethylstilbestrol). file://www.cancer.gov/cancertopics/causes/des/persons-exposed-to-des (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     National Cancer Institute. Clinician information: DES daughters - women exposed in utero. file://www.cancer.gov/cancertopics/causes/des/daughters-exposed-to-des (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/125\">",
"      Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/126\">",
"      Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/127\">",
"      Moscicki AB, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004; 190:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/128\">",
"      Nath R, Mant C, Luxton J, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 2007; 57:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/129\">",
"      Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010; 9:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/130\">",
"      Tam LS, Chan PK, Ho SC, et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res (Hoboken) 2011; 63:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/131\">",
"      Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus 2010; 19:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/132\">",
"      Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010; 8:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/133\">",
"      Yabroff KR, Saraiya M, Meissner HI, et al. Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007. Ann Intern Med 2009; 151:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/134\">",
"      Forbes C, Jepson R, Martin-Hirsch P. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev 2002; :CD002834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/135\">",
"      Yabroff KR, Mangan P, Mandelblatt J. Effectiveness of interventions to increase Papanicolaou smear use. J Am Board Fam Pract 2003; 16:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/136\">",
"      Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/137\">",
"      Batal H, Biggerstaff S, Dunn T, Mehler PS. Cervical cancer screening in the urgent care setting. J Gen Intern Med 2000; 15:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/138\">",
"      Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 2005; 97:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/139\">",
"      Sung HY, Kearney KA, Miller M, et al. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 2000; 88:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/140\">",
"      Stuart GC, McGregor SE, Duggan MA, Nation JG. Review of the screening history of Alberta women with invasive cervical cancer. CMAJ 1997; 157:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/141\">",
"      Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/142\">",
"      ACOG Committee on Quality Improvement and Patient Safety. ACOG committee opinion #329. Tracking and reminder systems. Obstet Gynecol 2006; 107:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/143\">",
"      Gordon NP, Hiatt RA, Lampert DI. Concordance of self-reported data and medical record audit for six cancer screening procedures. J Natl Cancer Inst 1993; 85:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/16/38154/abstract/144\">",
"      Everett T, Bryant A, Griffin MF, et al. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev 2011; :CD002834.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7575 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-C175512C90-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38154=[""].join("\n");
var outline_f37_16_38154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THE PAPANICOLAOU SMEAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cytology report",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bethesda classification system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Test characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Follow-up of abnormal cytology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HPV TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary HPV screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Use in areas with limited resources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Follow-up of HPV testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8372719\">",
"      - Normal Pap smear and positive HPV test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H440700697\">",
"      - HPV genotyping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HPV testing as triage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHER SCREENING MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Visual inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Computerized Pap screening or rescreening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1146544\">",
"      RISKS OF SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SCREENING PARAMETERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Initial screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Discontinuing screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Screening frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      HPV vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prior hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16975495\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16975503\">",
"      - Diethylstilbestrol (DES) exposed women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15399523\">",
"      - Immunocompromised women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      RECOMMENDATIONS OF PROFESSIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H286231691\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Starting age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Stopping age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51076976\">",
"      - Screening modality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Frequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Women who have undergone hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      International perspective",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      ADEQUACY OF SCREENING AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7575\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7575|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/32/41473\" title=\"algorithm 1\">",
"      HPV DNA testing cervical cancer screening over 30",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?33/14/34021\" title=\"algorithm 2\">",
"      Genotyping HPV HR and cytology in women 30 and over",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7575|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/20/4423\" title=\"figure 1\">",
"      CIN terminology and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7575|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/59/33715\" title=\"picture 1\">",
"      Normal pap smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/7/35956\" title=\"picture 2\">",
"      Abnormal pap smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7575|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/51/19261\" title=\"table 1\">",
"      Bethesda class cervix cytol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/21/24925\" title=\"table 2\">",
"      US recs cerv cancer screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/32/11790\" title=\"table 3\">",
"      Intl cerv cancer screen policies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8248?source=related_link\">",
"      Cervical cancer screening tests: Evidence of effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25156?source=related_link\">",
"      Cervical cancer screening tests: Visual inspection methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=related_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=related_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=related_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/53/8019?source=related_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2515?source=related_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/44/17092?source=related_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/8/15491?source=related_link\">",
"      Patient information: Pap tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/57/14227?source=related_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36934?source=related_link\">",
"      Screening for cervical cancer in HIV infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19160?source=related_link\">",
"      Screening for cervical cancer in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_16_38155="Causes of NAION";
var content_f37_16_38155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes and risk factors for NAION (nonarteritic anterior ischemic optic neuropathy)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Atherosclerosis risk factors, especially hypertension, diabetes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Small optic cup, \"disc at risk\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Coronary bypass",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Spine surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Radical neck dissection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cataract surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Others, especially if major blood loss, hypotension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Major blood loss from other causes, eg, trauma, gastrointestinal bleeding",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prothrombotic conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nocturnal hypotension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sleep apnea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renal Failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Phophodiesterase-5 inhibitors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Interferon-alpha",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Amiodarone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sympathomimetics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Migraine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carotid dissection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Genetic factors",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Not all have been proven associated in case-control studies.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38155=[""].join("\n");
var outline_f37_16_38155=null;
var title_f37_16_38156="Cholestatic causes jaundice";
var content_f37_16_38156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cholestatic conditions that can produce jaundice",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intrahepatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcoholic hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drug toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pure cholestasis - anabolic and contraceptive steroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixed cholestasis/hepatitis - chlorpromazine, erythromycin estolate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic cholestasis - chlorpromazine and prochlorperazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary biliary cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary sclerosing cholangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vanishing bile duct syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic rejection of liver transplants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inherited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign recurrent cholestasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Progressive intrahepatic familial cholestasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gilbert's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Crigler-Najjar syndrome types 1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dubin-Johnson syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rotor syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alagille syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestasis of pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-hepatobiliary sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign postoperative cholestasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraneoplastic syndrome (Stauffer's syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extrahepatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cholangiocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pancreatic cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gallbladder cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ampullary cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignant involvement of the porta hepatis lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Choledocholithiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primary sclerosing cholangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        AIDS cholangiopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AIDS: acquired immunodeficiency syndrome.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38156=[""].join("\n");
var outline_f37_16_38156=null;
var title_f37_16_38157="Ventilatory response to hypercapnia";
var content_f37_16_38157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Ventilatory response to hypercapnia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 286px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Beginning at a normal ventilation of 5 to 8 L/min and a PaCO",
"    <sub>",
"     2",
"    </sub>",
"    = 40 mmHg, ventilation increases linearly as PCO",
"    <sub>",
"     2",
"    </sub>",
"    rises. In normal individuals there is a range of responsiveness between 2 and 5 L/min/mmHg rise in PCO",
"    <sub>",
"     2",
"    </sub>",
"    . Hypoxemia heightens the response and shifts the curve up and to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38157=[""].join("\n");
var outline_f37_16_38157=null;
var title_f37_16_38158="Evolution of hepatic encephal";
var content_f37_16_38158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Evolution of hepatic encephalopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 315px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38158=[""].join("\n");
var outline_f37_16_38158=null;
var title_f37_16_38159="Galeazzi test";
var content_f37_16_38159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Galeazzi test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is positioned as shown. The knee is lower on the affected side because of posterior displacement in the developmentally dysplastic hip (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_16_38159=[""].join("\n");
var outline_f37_16_38159=null;
